Alpha-conotoxin peptides

ABSTRACT

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

CROSS-REFERENCE TO RELATED APPLICATION

The present application is a division of U.S. patent application Ser. No. 12/706,911 filed 17 Feb. 2010, now U.S. Pat. No. 7,902,153, which in turn is a division of U.S. patent application Ser. No. 11/869,480 filed 9 Oct. 2007, now U.S. Pat. No. 7,666,840, which in turn is a division of U.S. patent application Ser. No. 10/895,372 filed 21 Jul. 2004, now U.S. Pat. No. 7,279,549, which in turn is a division of U.S. patent application Ser. No. 09/493,795 filed 28 Jan. 2000, now U.S. Pat. No. 6,797,808. U.S. patent application Ser. No. 09/493,795 is related to and claims priority under 35 U.S.C. §119(e) to U.S. provisional patent application Ser. No. 60/118,381, filed 29 Jan. 1999. Each application is incorporated herein by reference.

This invention was made with Government support under Grant No. PO1 GM48677 awarded by the National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.

SEQUENCE SUBMISSION

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is entitled 2323248SequenceListing.txt, was created on 7 Mar. 2011 and is 252 kb in size. The information in the electronic format of the Sequence Listing is part of the present application and is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference, and for convenience are referenced in the following text by author and date and are listed alphabetically by author in the appended bibliography.

The predatory cone snails (Conus) have developed a unique biological strategy. Their venom contains relatively small peptides that are targeted to various neuromuscular receptors and may be equivalent in their pharmacological diversity to the alkaloids of plants or secondary metabolites of microorganisms. Many of these peptides are among the smallest nucleic acid-encoded translation products having defined conformations, and as such, they are somewhat unusual. Peptides in this size range normally equilibrate among many conformations. Proteins having a fixed conformation are generally much larger.

The cone snails that produce these peptides are a large genus of venomous gastropods comprising approximately 500 species. All cone snail species are predators that inject venom to capture prey, and the spectrum of animals that the genus as a whole can envenomate is broad. A wide variety of hunting strategies are used; however, every Conus species uses fundamentally the same basic pattern of envenomation.

Several peptides isolated from Conus venoms have been characterized. These include the α-, μ- and ω-conotoxins which target nicotinic acetylcholine receptors, muscle sodium channels, and neuronal calcium channels, respectively (Olivera et al., 1985). Conopressins, which are vasopressin analogs, have also been identified (Cruz et al. 1987). In addition, peptides named conantokins have been isolated from Conus geographus and Conus tulipa (Mena et al., 1990; Haack et al., 1990).

The α-conotoxins are small peptides highly specific for neuromuscular junction nicotinic acetylcholine receptors (Gray et al., 1981; Marshall and Harvey, 1990; Blount et al., 1992; Jacobsen et al., 1997) or highly specific for neuronal nicotinic acetylcholine receptors (Fainzilber et al., 1994; Johnson et al., 1995; Cartier et al., 1996; Luo et al., 1998). The α-conotoxins with specificity for neuromuscular junction nicotinic acetylcholine receptors are used as neuromuscular blocking agents for use in conjunction with surgery, as disclosed in U.S. patent application Ser. No. 09/488,799, filed 21 Jan. 2000, incorporated by reference herein. Additional α-conotoxins and uses for them have been described in U.S. Pat. Nos. 4,447,356 (Olivera et al., 1984); 5,432,155; 5,514,774, each incorporated herein by reference.

Additional uses for α-conotoxins are described in U.S. Ser. No. 09/219,446, filed 22 Dec. 1998, incorporated herein by reference. In this application, α-conotoxins with specificity for neuronal nicotinic acetylcholine receptors are used for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma.

It is desired to provide additional α-conotoxin peptides having uses as described herein.

SUMMARY OF THE INVENTION

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

More specifically, the present invention is directed to α-conotoxin peptides having the general formula I:

Xaa₁-Xaa₂-Xaa₃-Xaa₄-Xaa₅-Cys-Cys-Xaa₆-Xaa₇-Xaa₈-Xaa₉-Cys-Xaa₁₀-Xaa₁₁-Xaa₁₂-Cys-Xaa₁₃ (SEQ ID NO:1), wherein Xaa₁ is des-Xaa₁, Ile, Leu or Val; Xaa₂ is des-Xaa₂, Ala or Gly; Xaa₃ is des-Xaa₃, Gly, Trp (D or L), neo-Trp, halo-Trp or any unnatural aromatic amino acid; Xaa₄ is des-Xaa₄, Asp, Phe, Gly, Ala, Glu, γ-carboxy-Glu (Gla) or any unnatural aromatic amino acid; Xaa₅ is Glu, Gla, Asp, Ala, Thr, Ser, Gly, Ile, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₆ is Ser, Thr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₇ is Asp, Glu, Gla, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₈ is Ser, Thr, Asn, Ala, Gly, Arg, Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, His, halo-His, Pro or hydroxy-Pro; Xaa₉ is Thr, Ser, Ala, Asp, Asn, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₀ is Gly, Ser, Thr, Ala, Asn, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₁ is Gln, Leu, His, halo-His, Trp (D or L), halo-Trp, neo-Trp, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid or any unnatural aromatic amino acid; Xaa₁₂ is Asn, His, halo-His, Ile, Leu, Val, Gln, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₃ is des-Xaa₁₃, Val, Ile, Leu, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid. The C-terminus may contain a free carboxyl group or an amide group. The halo is chlorine, bromine or iodine, preferably iodine for Tyr and His and preferably bromine for Trp. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.

More specifically, the present invention is directed to α-conotoxin peptides having the general formula II:

Xaa₁-Xaa₂-Xaa₃-Xaa₄-Cys-Cys-Xaa₅-Xaa₆-Xaa₇-Xaa₈-Cys-Xaa₉-Xaa₁₀-Xaa₁₁-Xaa₁₂-Xaa₁₃-Xaa₁₄-Cys-Xaa₁₅-Xaa₁₆-Xaa₁₇ (SEQ ID NO: 2), wherein Xaa₁ is des-Xaa₁, Asp, Glu or γ-carboxy-Glu (Gla); Xaa₂ is des-Xaa₂, Gln, Ala, Asp, Glu, Gla; Xaa₃ is des-Xaa₃, Gly, Ala, Asp, Glu, Gla, Pro or hydroxy-Pro; Xaa₄ is des-Xaa₄, Gly, Glu, Gla, Gln, Asp, Asn, Pro or hydroxy-Pro; Xaa₅ is Ser, Thr, Gly, Glu, Gla, Asn, Trp (D or L), neo-Trp, halo-Trp, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₆ is Asp, Asn, His, halo-His, Thr, Ser, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₇ is Pro or hydroxy-Pro; Xaa₈ is Ala, Ser, Thr, Asp, Val, Ile, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₉ is Gly, Ile, Leu, Val, Ala, Thr, Ser, Pro, hydroxy-Pro, Phe, Trp (D or L), neo-Trp, halo-Trp, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid or any unnatural aromatic amino acid; Xaa₁₀ is Ala, Asn, Phe, Pro, hydroxy-Pro, Glu, Gla, Gln, His, halo-His, Val, Ser, Thr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₁ is Thr, Ser, His, halo-His, Leu, Ile, Val, Asn, Met, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₁₂ is Asn, Pro, hydroxy-Pro, Gln, Ser, Thr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₁₃ is des-Xaa₁₃, Gly, Thr, Ser, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₁₄ is des-Xaa₁₄, Ile, Val, Asp, Leu, Phe, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; and Xaa₁₅ is des-Xaa₁₅, Gly, Ala, Met, Ser, Thr, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₆ is des-Xaa₁₆, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₇ is des-Xaa₁₇, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid. The C-terminus may contain a free carboxyl group or an amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for His or Tyr and bromine for Trp. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.

More specifically, the present invention is directed to α-conotoxin peptides having the general formula III:

Xaa₁-Xaa₂-Xaa₃-Xaa₄-Xaa₅-Cys-Cys-Xaa₆-Xaa₇-Xaa₈-Xaa₉-Cys-Xaa₁₀-Xaa₁₁-Xaa₁₂-Xaa₁₃-Xaa₁₄-Xaa₁₅-Xaa₁₆-Cys-Xaa₁₇-Xaa₁₈-Xaa₁₉-Xaa₂₀-Xaa₂₁-Xaa₂₂-Xaa₂₃-Xaa₂₄ (SEQ ID NO: 3), wherein Xaa₁ is des-Xaa₁, Ser or Thr; Xaa₂ is des-Xaa₂, Asp, Glu, γ-carboxy-Glu (Gla), Asn, Ser or Thr; Xaa₃ is des-Xaa₃, Ala, Gly, Asn, Ser, Thr, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₄ is des-Xaa₄, Ala, Val, Leu, Ile, Gly, Glu, Gla, Gln, Asp, Asn, Phe, Pro, hydroxy-Pro or any unnatural aromatic amino acid; Xaa₅ is des-Xaa₅, Thr, Ser, Asp, Glu, Gla, Gln, Gly, Val, Asp, Asn, Ala, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₆ is Thr, Ser, Asp, Asn, Met, Val, Ala, Gly, Leu, Ile, Phe, any unnatural aromatic amino acid, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₇ is Ile, Leu, Val, Ser, Thr, Gln, Asn, Asp, Arg, His, halo-His, Phe, any unnatural aromatic amino acid, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₈ is Pro, hydroxy-Pro, Ser, Thr, Ile, Asp, Leu, Val, Gly, Ala, Phe, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₉ is Val, Ala, Gly, Ile, Leu, Asp, Ser, Thr, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₀ is His, halo-His, Arg, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Asn, Ala, Ser, Thr, Phe, Ile, Leu, Gly, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₁₁ is Leu, Gln, Val, Ile, Gly, Met, Ala, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, Ser, Thr, Arg, homoarginine, ornithine, any unnatural basic amino acid, Asn, Glu, Gla, Gln, Phe, Trp (D or L), neo-Trp, halo-Trp or any unnatural aromatic amino acid; Xaa₁₂ is Glu, Gla, Gln, Asn, Asp, Pro, hydroxy-Pro, Ser, Gly, Thr, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, Arg, homoarginine, ornithine, any unnatural basic amino acid, Phe, His, halo-His, any unnatural aromatic amino acid, Leu, Met, Gly, Ala, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₁₃ is His, halo-His, Asn, Thr, Ser, Ile, Val, Leu, Phe, any unnatural aromatic amino acid, Arg, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Try, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₁₄ is Ser, Thr, Ala, Gln, Pro, hydroxy-Pro, Gly, Ile, Leu, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₅ is Asn, Glu, Gla, Asp, Gly, His, halo-His, Ala, Leu, Gln, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa₁₆ is Met, Ile, Thr, Ser, Val, Leu, Pro, hydroxy-Pro, Phe, any unnatural aromatic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr, any unnatural hydroxy containing amino acid, Glu, Gla, Ala, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₇ is des-Xaa₁₇, Gly, Asp, Asn, Ala, Ile, Leu, Ser, Thr, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₈ is des-Xaa₁₈, Gly, Glu, Gla, Gln, Trp (D or L), neo, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₁₉ is des-Xaa₁₉, Ser, Thr, Val, Ile, Ala, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₂₀ is des-Xaa₂₀, Val, Asp, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₂₁ is des-Xaa₂₁, Asn, Pro or hydroxy-Pro; Xaa₂₂ is des-Xaa₂₂, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa₂₃ is des-Xaa₂₃, Ser or Thr; Xaa₂₄ is des-Xaa₂₄, Leu, Ile or Val; with the proviso that (a) Xaa₅ is not Gly, when Xaa₁ is des-Xaa₁, Xaa₂ is des-Xaa₂, Xaa₃ is des-Xaa₃, Xaa₄ is des-Xaa₄, Xaa₆ is Ser, Xaa₇ is His, Xaa₈ is Pro, Xaa₉ is Ala, Xaa₁₀ is Ser, Xaa₁₁ is Val, Xaa₁₂ is Asn, Xaa₁₃ is Asn, Xaa₁₄ is Pro, Xaa₁₅ is Asp, Xaa₁₆ is Ile, Xaa₁₇ is des-Xaa₁₇, Xaa₁₈ is des-Xaa₁₈, Xaa₁₉ is des-Xaa₁₉, Xaa₂₀ is des-Xaa₂₀, Xaa₂₁ is des-Xaa₂₁, Xaa₂₂ is des-Xaa₂₂, Xaa₂₃ is des-Xaa₂₃, and Xaa₂₄ is des-Xaa₂₄. The C-terminus may contain a free carboxyl group or an amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for His and Tyr and bromine for Trp. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.

The present invention is also directed to novel specific α-conotoxin peptides of general formula I having the formulas:

(SEQ ID NO: 4) Asp-Xaa₁-Cys-Cys-Ser-Asp-Ser-Arg-Cys-Gly-Xaa₂- Asn-Cys-Leu; (SEQ ID NO: 5) Ala-Cys-Cys-Ser-Asp-Arg-Arg-Cys-Arg-Xaa₃-Arg- Cys; (SEQ ID NO: 6) Phe-Thr-Cys-Cys-Arg-Arg-Gly-Thr-Cys-Ser-Gln- His-Cys; (SEQ ID NO: 7) Asp-Xaa₄-Cys-Cys-Arg-Arg-His-Ala-Cys-Thr-Leu- Ile-Cys; (SEQ ID NO: 8) Asp-Xaa₄-Cys-Cys-Arg-Xaa₅-Xaa₅-Cys-Thr-Leu-Ile- Cys; (SEQ ID NO: 9) Gly-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Arg-Xaa₄-Arg- Cys-Arg; (SEQ ID NO: 10) Gly-Gly-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Ala-Xaa₃- Arg-Cys; (SEQ ID NO: 11) Ile-Ala-Xaa₃-Asp-Ile-Cys-Cys-Ser-Xaa₁-Xaa₅-Asp- Cys-Asn-His-Xaa₂-Cys-Val; and (SEQ ID NO: 12) Gly-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Xaa₂-His-Gln- Cys, wherein Xaa₁ is Glu or γ-carboxy-Glu (Gla); Xaa₂ is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa₃ is Trp (D or L), halo-Trp or neo-Trp; Xaa₄ is Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; and Xaa₅ is Pro or hydroxy-Pro; and the C-terminus contains a carboxyl or amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for Tyr and bromine for Trp. In addition, the His residues may be substituted with halo-His; the Arg residues may be substituted by Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Tyr residues may be substituted with any unnatural hydroxy containing amino acid; the Ser residues may be substituted with Thr; the Thr residues may be substituted with Ser; and the Phe and Trp residues may be substituted with any unnatural aromatic amino acid. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.

More specifically, the present invention is directed to the following α-conotoxin peptides of general formula I:

Im1.1: SEQ ID NO: 4, wherein Xaa₁ is Glu and Xaa₂ is Lys; Im1.2: SEQ ID NO: 5, wherein Xaa₃ is Trp; Rg1.2: SEQ ID NO: 6; Rg1.6: SEQ ID NO: 7, wherein Xaa₄ is Tyr; Rg1.6A: SEQ ID NO: 8, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Rg1.7: SEQ ID NO: 9, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Rg1.9: SEQ ID NO: 10, wherein Xaa₃ is Trp and Xaa₅ is Pro; Rg1.10: SEQ ID NO: 11, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₃ is Trp and Xaa₅ is Pro; and Rg1.11: SEQ ID NO: 12, wherein Xaa₂ is Lys and Xaa₅ is Pro. The C-terminus of Im1.1, Rg1.7 an Rg1.10 preferably contains a free carboxyl group. The C-terminus of Im1.2, Rg1.2, Rg1.6, Rg1.6A, Rg1.9 and Rg1.11 preferably contains an amide group.

The present invention is further directed to novel specific α-conotoxin peptides of general formula II having the formulas:

(SEQ ID NO: 13) Cys-Cys-Ser-Asp-Xaa₅-Ala-Cys-Xaa₂-Gln-Thr-Xaa₅- Gly-Cys-Arg; (SEQ ID NO: 14) Cys-Cys-Xaa₁-Asn-Xaa₅-Ala-Cys-Arg-His-Thr-Gln- Gly-Cys; (SEQ ID NO: 15) Gly-Cys-Cys-Xaa₃-His-Xaa₅-Ala-Cys-Gly-Arg-His- Xaa₄-Cys; (SEQ ID NO: 16) Ala-Xaa₅-Cys-Cys-Asn-Asn-Xaa₅-Ala-Cys-Val-Xaa₂- His-Arg-Cys; (SEQ ID NO: 17) Ala-Xaa₅-Gly-Cys-Cys-Asn-Asn-Xaa₅-Ala-Cys-Val- Xaa₂-His-Arg-Cys; (SEQ ID NO: 18) Xaa₅-Xaa₅-Cys-Cys-Asn-Asn-Xaa₅-Ala-Cys-Val-Xaa₂- His-Arg-Cys; (SEQ ID NO: 19) Asp-Xaa₁-Asn-Cys-Cys-Xaa₃-Asn-Xaa₅-Ser-Cys-Xaa₅- Arg-Xaa₅-Arg-Cys-Thr; (SEQ ID NO: 20) Gly-Cys-Cys-Ser-Thr-Xaa₅-Xaa₅-Cys-Ala-Val-Leu- Xaa₄-Cys; (SEQ ID NO: 21) Gly-Cys-Cys-Gly-Asn-Xaa₅-Asp-Cys-Thr-Ser-His- Ser-Cys; (SEQ ID NO: 42) Gly-Cys-Cys-Ser-Asn-Xaa₅-Xaa₅-Cys-Ala-His-Asn- Asn-Xaa₅-Asp-Cys-Arg; (SEQ ID NO: 154) Gly-Cys-Cys-Xaa₄-Asn-Xaa₅-Val-Cys-Xaa₂-Xaa₂- Xaa₄-Xaa₄-Cys-Xaa₃-Xaa₂; (SEQ ID NO: 155) Xaa₆-Xaa₁-Xaa₅-Gly-Cys-Cys-Arg-His-Xaa₅-Ala- Cys-Gly-Xaa₂-Asn-Arg-Cys; (SEQ ID NO: 156) Cys-Cys-Ala-Asp-Xaa₅-Asp-Cys-Arg-Phe-Arg- Xaa₅-Gly-Cys; (SEQ ID NO: 157) Gly-Cys-Cys-Xaa₄-Asn-Xaa₅-Ser-Cys-Xaa₃-Xaa₅- Xaa₂-Thr-Xaa₄-Cys-Ser-Xaa₃-Xaa₂; (SEQ ID NO: 158) Cys-Cys-Ser-Asn-Xaa₅-Thr-Cys-Xaa₂-Xaa₁-Thr- Xaa₄-Gly-Cys; (SEQ ID NO: 159) Cys-Cys-Ala-Asn-Xaa₅-Ile-Cys-Xaa₂-Asn-Thr- Xaa₅-Gly-Cys; (SEQ ID NO: 160) Cys-Cys-Asn-Asn-Xaa₅-Thr-Cys-Xaa₂-Xaa₁-Thr- Xaa₄-Gly-Cys; (SEQ ID NO: 161) Cys-Cys-Ser-Asn-Xaa₅-Val-Cys-Xaa₂-Xaa₁-Thr- Xaa₄-Gly-Cys; (SEQ ID NO: 162) Gly-Gly-Cys-Cys-Ser-Xaa₄-Xaa₅-Xaa₅-Cys-Ile- Ala-Ser-Asn-Xaa₅-Xaa₂-Cys-Gly; (SEQ ID NO: 163) Gly-Cys-Cys-Ser-His-Xaa₅-Val-Cys-Ser-Ala- Met-Ser-Xaa₅-Ile-Cys; (SEQ ID NO: 164) Gly-Cys-Cys-Xaa₂-Asn-Xaa₅-Xaa₄-Cys-Gly-Ala- Ser-Xaa₂-Thr-Xaa₄-Cys; (SEQ ID NO: 165) Gly-Cys-Cys-Ser-Xaa₄-Xaa₅-Xaa₅-Cys-Phe-Ala- Thr-Asn-Xaa₅-Asp-Cys; (SEQ ID NO: 166) Gly-Gly-Cys-Cys-Ser-Xaa₄-Xaa₅-Xaa₅-Cys-Ile- Ala-Asn-Asn-Xaa₅-Leu-Cys-Ala; (SEQ ID NO: 167) Gly-Gly-Cys-Cys-Ser-Xaa₄-Xaa₅-Xaa₅-Cys-Ile- Ala-Asn-Asn-Xaa₅-Phe-Cys-Ala; (SEQ ID NO: 168) Asp-Cys-Cys-Ser-Asn-Xaa₅-Xaa₅-Cys-Ser-Gln- Asn-Asn-Xaa₅-Asp-Cys-Met; and (SEQ ID NO: 169) Asp-Cys-Cys-Ser-Asn-Xaa₅-Xaa₅-Cys-Ala-His- Asn-Asn-Xaa₅-Asp-Cys-Arg, wherein Xaa₁ is Glu or γ-carboxy-Glu (Gla); Xaa₂ is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa₃ is Trp (D or L), halo-Trp or neo-Trp; Xaa₄ is Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; and Xaa₅ is Pro or hydroxy-Pro; and the C-terminus contains a carboxyl or amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for Tyr and bromine for Trp. In addition, the His residues may be substituted with halo-His; the Arg residues may be substituted by Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Tyr residues may be substituted with any unnatural hydroxy containing amino acid; the Ser residues may be substituted with Thr; the Thr residues may be substituted with Ser; and the Phe and Trp residues may be substituted with any unnatural aromatic amino acid. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.

More specifically, the present invention is directed to the following α-conotoxin peptides of general formula II:

Sn1.1: SEQ ID NO: 13, wherein Xaa₂ is Lys and Xaa₅ is Pro; Sn1.2: SEQ ID NO: 14, wherein Xaa₁ is Glu and Xaa₅ is Pro; Sl1.3: SEQ ID NO: 15, wherein Xaa₃ is Trp, Xaa₄ is Tyr and Xaa₅ is Pro; A1.2: SEQ ID NO: 16, wherein Xaa₂ is Lys and Xaa₅ is Pro; Bu1.1: SEQ ID NO: 17, wherein Xaa₂ is Lys and Xaa₅ is Pro; Bu1.2: SEQ ID NO: 18, wherein Xaa₂ is Lys and Xaa₅ is Pro; Bu1.3: SEQ ID NO: 19, wherein Xaa₁ is Glu, Xaa₃ is Trp and Xaa₅ is Pro; Bu1.4: SEQ ID NO: 20, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Cr1.3: SEQ ID NO: 21, wherein Xaa₅ is Pro; Di1.1: SEQ ID NO: 42 wherein Xaa₅ is Pro; Ms1.7: SEQ ID NO: 154, wherein Xaa₂ is Lys, Xaa₃ is Trp, Xaa₄ is Tyr and Xaa₅ is Pro; P1.7: SEQ ID NO: 155, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₅ is Pro and Xaa₆ is Gln; Ms1.2: SEQ ID NO: 156, wherein Xaa₅ is Pro; Ms1.3: SEQ ID NO: 157, wherein Xaa₂ is Lys, Xaa₃ is Trp, Xaa₄ is Tyr and Xaa₅ is Pro; Ms1.4: SEQ ID NO: 158, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Ms1.5: SEQ ID NO: 159, wherein Xaa₂ is Lys and Xaa₅ is Pro; Ms1.8: SEQ ID NO: 160, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Ms1.9: SEQ ID NO: 161, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Bt1.7: SEQ ID NO: 162, wherein Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Lv1.5: SEQ ID NO: 163, wherein Xaa₅ is Pro; Ms1.10: SEQ ID NO: 164, wherein Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Om1.1: SEQ ID NO: 165, wherein Xaa₄ is Tyr and Xaa₅ is Pro; R1.6: SEQ ID NO: 166, wherein Xaa₄ is Tyr and Xaa₅ is Pro; R1.7: SEQ ID NO: 167, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Vr1.1: SEQ ID NO: 168, wherein Xaa₅ is Pro; and Vr1.2: SEQ ID NO: 169, wherein Xaa₅ is Pro. The C-terminus preferably contains a carboxyl group for the peptides Sn1.1, Sn1.2, Cr1.3, Di1.1, Ms1.2, Ms1.4, Ms1.5, Ms1.8, Ms1.9, Vr1.1 and Vr1.2. The C-terminus of the other peptides preferably contains an amide group.

The present invention is also directed to novel specific α-conotoxin peptides of general formula III having the formulas:

(SEQ ID NO: 22) Gly-Cys-Cys-Ser-Asn-Xaa₅-Val-Cys-His-Leu-Xaa₁- His-Ser-Asn-Met-Cys; (SEQ ID NO: 23) Gly-Cys-Cys-Ser-Asn-Xaa₅-Val-Cys-Arg-Gln-Asn- Asn-Ala-Xaa₁-Xaa₄-Cys-Arg; (SEQ ID NO: 24) Xaa₅-Gln-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Ile-Cys-Arg; (SEQ ID NO: 25) Xaa₅-Xaa₁-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Ile-Cys-Arg; (SEQ ID NO: 26) Xaa₅-Gln-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Ile-Cys-Asp; (SEQ ID NO: 27) Xaa₅-Arg-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Ile-Cys-Arg; (SEQ ID NO: 28) Xaa₅-Gln-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Gly-Ile-Cys-Arg; (SEQ ID NO: 29) Xaa₅-Gln-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Thr-Cys-Arg; (SEQ ID NO: 30) Xaa₅-Gln-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Val-Cys-Arg; (SEQ ID NO: 31) Xaa₅-Gln-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Ile- Asp-His-Xaa₅-Xaa₁-Ile-Cys-Arg; (SEQ ID NO: 32) Xaa₅-Gln-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Ile-Cys-Arg-Arg-Arg-Arg; (SEQ ID NO: 33) Gly-Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ala-Val- Asn-His-Xaa₅-Xaa₁-Leu-Cys; (SEQ ID NO: 34) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ser-Val-Asn- His-Xaa₅-Xaa₁-Leu-Cys; (SEQ ID NO: 35) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val-Asp- His-Xaa₅-Xaa₁-Ile-Cys; (SEQ ID NO: 36) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ser-Gly-Xaa₂- Thr-Gln-Xaa₁-Xaa₅-Cys-Arg-Xaa₁-Ser; (SEQ ID NO: 37) Xaa₅-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ser-Gly-Asn- Asn-Xaa₅-Xaa₁-Phe-Cys-Arg-Gln; (SEQ ID NO: 38) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ser-Gly-Asn- Asn-Xaa₅-Xaa₁-Phe-Cys-Arg-Gln; (SEQ ID NO: 39) Gly-Cys-Cys-Ser-His-Xaa₅-Xaa₅-Cys-Ala-Met-Asn- Asn-Xaa₅-Asp-Xaa₄-Cys; (SEQ ID NO: 40) Gly-Cys-Cys-Ser-His-Xaa₅-Xaa₅-Cys-Phe-Leu-Asn- Asn-Xaa₅-Asp-Xaa₄-Cys; (SEQ ID NO: 41) Gly-Cys-Cys-Ser-Asn-Xaa₅-Xaa₅-Cys-Ile-Ala-Xaa₂- Asn-Xaa₅-His-Met-Cys-Gly; (SEQ ID NO: 43) Gly-Cys-Cys-Ser-Asn-Xaa₅-Ala-Cys-Ala-Gly-Asn- Asn-Xaa₅-His-Val-Cys-Arg-Gln; (SEQ ID NO: 44) Gly-Cys-Cys-Ser-Arg-Xaa₅-Ala-Cys-Ile-Ala-Asn- Asn-Xaa₅-Asp-Leu-Cys; (SEQ ID NO: 45) Gly-Cys-Cys-Ser-Asn-Xaa₅-Val-Cys-His-Val-Xaa₁- His-Xaa₅-Xaa₁-Leu-Cys-Arg-Arg-Arg-Arg; (SEQ ID NO: 46) Gly-Gly-Cys-Cys-Ser-Phe-Xaa₅-Ala-Cys-Arg-Xaa₂- Xaa₅-Arg-Xaa₅-Xaa₁-Met-Cys-Gly; (SEQ ID NO: 47) Xaa₅-Xaa₁-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Asn-Ser- Ser-His-Xaa₅-Xaa₁-Leu-Cys-Gly; (SEQ ID NO: 48) Xaa₅-Gln-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Asn-Val- Gly-His-Xaa₅-Xaa₁-Leu-Cys-Gly; (SEQ ID NO: 49) Xaa₆-Val-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Asn-Val- Gly-His-Xaa₅-Xaa₁-Ile-Cys-Gly; (SEQ ID NO: 50) Gly-Cys-Cys-Ser-Arg-Xaa₅-Xaa₅-Cys-Ile-Ala-Asn- Asn-Xaa₅-Asp-Leu-Cys; (SEQ ID NO: 51) Xaa₅-Gln-Cys-Cys-Ser-His-Leu-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Ile-Cys-Arg; (SEQ ID NO: 52) Gly-Cys-Cys-Ser-Xaa₄-Phe-Asp-Cys-Arg-Met-Met- Phe-Xaa₅-Xaa₁-Met-Cys-Gly-Xaa₃-Arg; (SEQ ID NO: 53) Gly-Gly-Cys-Cys-Ser-Phe-Ala-Ala-Cys-Arg-Xaa₂- Xaa₄-Arg-Xaa₅-Xaa₁-Met-Cys-Gly; (SEQ ID NO: 54) Gly-Gly-Cys-Cys-Phe-His-Xaa₅-Val-Cys-Xaa₄-Ile- Asn-Leu-Leu-Xaa₁-Met-Cys-Arg-Gln-Arg; (SEQ ID NO: 55) Ser-Ala-Thr-Cys-Cys-Asn-Xaa₄-Xaa₅-Xaa₅-Cys-Xaa₄- Xaa₁-Thr-Xaa₄-Xaa₅-Xaa₁-Ser-Cys-Leu; (SEQ ID NO: 56) Ala-Cys-Cys-Ala-Xaa₄-Xaa₅-Xaa₅-Cys-Phe-Xaa₁-Ala- Xaa₄-Xaa₅-Xaa₁-Arg-Cys-Leu; (SEQ ID NO: 57) Asn-Ala-Xaa₁-Cys-Cys-Xaa₄-Xaa₄-Xaa₅-Xaa₅-Cys-Xaa₄- Xaa₁-Ala-Xaa₄-Xaa₅-Xaa₁-Ile-Cys-Leu; (SEQ ID NO: 170) Xaa₁-Cys-Cys-Thr-Asn-Xaa₅-Val-Cys-His-Ala-Xaa₁- His-Gln-Xaa₁-Leu-Cys-Ala-Arg-Arg-Arg; (SEQ ID NO: 171) Gly-Cys-Cys-Ser-Asn-Xaa₅-Val-Cys-His-Leu-Xaa₁- His-Ser-Asn-Leu-Cys; (SEQ ID NO: 172) Xaa₁-Cys-Cys-Thr-Asn-Xaa₅-Val-Cys-His-Val-Xaa₁- His-Gln-Xaa₁-Leu-Cys-Ala-Arg-Arg-Arg; (SEQ ID NO: 173) Xaa₆-Xaa₁-Cys-Cys-Ser-Xaa₄-Xaa₅-Ala-Cys-Asn-Leu- Asp-His-Xaa₅-Xaa₁-Leu-Cys; (SEQ ID NO: 174) Xaa₅-Xaa₁-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Asn-Ser- Thr-His-Xaa5-Xaa₁-Leu-Cys-Gly; (SEQ ID NO: 175) Leu-Asn-Cys-Cys-Met-Ile-Xaa₅-Xaa₅-Cys-Xaa₃-Xaa₂- Xaa₂-Xaa₄-Gly-Asp-Arg-Cys-Ser-Xaa₁-Val-Arg; (SEQ ID NO: 176) Ala-Phe-Gly-Cys-Cys-Asp-Leu-Ile-Xaa₅-Cys-Leu- Xaa₁-Arg-Xaa₄-Gly-Asn-Arg-Cys-Asn-Xaa₁-Val-His; (SEQ ID NO: 177) Leu-Gly-Cys-Cys-Asn-Val-Thr-Xaa₅-Cys-Xaa₃-Xaa₁- Xaa₂-Xaa₄-Gly-Asp-Xaa₂-Cys-Asn-Xaa₁-Val-Arg; (SEQ ID NO: 178) Asp-Xaa₁-Cys-Cys-Ser-Asn-Xaa₅-Ala-Cys-Arg-Val- Asn-Asn-Xaa₅-His-Val-Cys-Arg-Arg-Arg; (SEQ ID NO: 179) Leu-Asn-Cys-Cys-Ser-Ile-Xaa₅-Gly-Cys-Xaa₃-Asn- Xaa₁-Xaa₄-Xaa₂-Asp-Arg-Cys-Ser-Xaa₂-Val-Arg; (SEQ ID NO: 180) Gly-Gly-Cys-Cys-Ser-His-Xaa₅-Val-Cys-Xaa₄-Phe- Asn-Asn-Xaa₅-Gln-Met-Cys-Arg; (SEQ ID NO: 181) Gly-Gly-Cys-Cys-Ser-His-Xaa₅-Val-Cys-Asn-Leu- Asn-Asn-Xaa₅-Gln-Met-Cys-Arg; (SEQ ID NO: 182) Gly-Cys-Cys-Ser-His-Xaa₅-Xaa₅-Cys-Xaa₄-Ala-Asn- Asn-Gln-Ala-Xaa₄-Cys-Asn; (SEQ ID NO: 183) Gly-Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ser-Val- Thr-His-Xaa₅-Xaa₁-Leu-Cys; (SEQ ID NO: 184) Gly-Gly-Cys-Cys-Ser-Xaa₄-Xaa₅-Ala-Cys-Ser-Val- Xaa₁-His-Gln-Asp-Leu-Cys-Asp; (SEQ ID NO: 185) Val-Ser-Cys-Cys-Val-Val-Arg-Xaa₅-Cys-Xaa₃-Ile- Arg-Xaa₄-Gln-Xaa₁-Xaa₁-Cys-Leu-Xaa₁-Ala-Asp- Xaa₅-Arg-Thr-Leu; (SEQ ID NO: 186) Xaa₆-Asn-Cys-Cys-Ser-Ile-Xaa₅-Gly-Cys-Xaa₃-Xaa₁- Xaa₂-Xaa₄-Gly-Asp-Xaa₂-Cys-Ser-Xaa₁-Val-Arg; (SEQ ID NO: 187) Gly-Cys-Cys-Ser-Asn-Xaa₅-Val-Cys-His-Leu-Xaa₁- His-Xaa₅-Asn-Ala-Cys; (SEQ ID NO: 188) Gly-Cys-Cys-Ser-Asn-Xaa₅-Ile-Cys-Xaa₄-Phe-Asn- Asn-Xaa₅-Arg-Ile-Cys-Arg; (SEQ ID NO: 189) Xaa₁-Cys-Cys-Ser-Gln-Xaa₅-Xaa₅-Cys-Arg-Xaa₃- Xaa₂-His-Xaa₅-Xaa₁-Leu-Cys-Ser; (SEQ ID NO: 190) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ala-Gly-Asn- Asn-Gln-His-Ile-Cys; (SEQ ID NO: 191) Gly-Cys-Cys-Ala-Val-Xaa₅-Ser-Cys-Arg-Leu-Arg- Asn-Xaa₅-Asp-Leu-Cys-Gly-Gly; (SEQ ID NO: 192) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val-Asn- Asn-Xaa₅-His-Ile-Cys; (SEQ ID NO: 193) Thr-Xaa₅-Xaa₁-Xaa₁-Cys-Cys-Xaa₅-Asn-Xaa₅-Xaa₅- Cys-Phe-Ala-Thr-Asn-Ser-Asp-Ile-Cys-Gly; (SEQ ID NO: 194) Asp-Ala-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Ser-Gly- Xaa₂-His-Gln-Asp-Leu-Cys; (SEQ ID NO: 195) Xaa₁-Asp-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Ser-Val- Gly-His-Gln-Asp-Leu-Cys; (SEQ ID NO: 196) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ala-Gly-Ser- Asn-Ala-His-Ile-Cys; (SEQ ID NO: 197) Xaa₁-Asp-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Ser-Val- Gly-His-Gln-Asp-Met-Cys; (SEQ ID NO: 198) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ala-Gly-Asn- Asn-Xaa₅-His-Ile-Cys; (SEQ ID NO: 199) Gly-Cys-Cys-Gly-Asn-Xaa₅-Ser-Cys-Ser-Ile-His- Ile-Xaa₅-Xaa₄-Val-Cys-Asn; (SEQ ID NO: 200) Thr-Asp-Ser-Xaa₁-Xaa₁-Cys-Cys-Leu-Asp-Ser-Arg- Cys-Ala-Gly-Gln-His-Gln-Asp-Leu-Cys-Gly; (SEQ ID NO: 201) Gly-Cys-Cys-Ser-Asn-Xaa₅-Xaa₅-Cys-Xaa₄-Ala-Asn- Asn-Gln-Ala-Xaa₄-Cys-Asn; (SEQ ID NO: 202) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ser-Val-Asn- Asn-Xaa₅-Asp-Ile-Cys; (SEQ ID NO: 203) Gly-Xaa₂-Cys-Cys-Ile-Asn-Asp-Ala-Cys-Arg-Ser- Xaa₂-His-Xaa₅-Gln-Xaa₄-Cys-Ser; (SEQ ID NO: 204) Gly-Cys-Cys-Xaa₄-Asn-Ile-Ala-Cys-Arg-Ile-Asn- Asn-Xaa₅-Arg-Xaa₄-Cys-Arg; (SEQ ID NO: 205) Gly-Cys-Cys-Ser-His-Xaa₅-Val-Cys-Arg-Phe-Asn- Xaa₄-Xaa₅-Xaa₂-Xaa₄-Cys-Gly; (SEQ ID NO: 206) Asp-Xaa₁-Cys-Cys-Ala-Ser-Xaa₅-Xaa₅-Cys-Arg-Leu- Asn-Asn-Xaa₅-Xaa₄-Val-Cys-His; (SEQ ID NO: 207) Gly-Cys-Cys-Ser-Asn-Xaa₅-Val-Cys-Xaa₃-Gln-Asn- Asn-Ala-Xaa₁-Xaa₄-Cys-Arg-Xaa₁-Ser; (SEQ ID NO: 208) Gly-Cys-Cys-Ser-His-Xaa₅-Xaa₅-Cys-Ala-Gln-Asn- Asn-Gln-Asp-Xaa₄-Cys; (SEQ ID NO: 209) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ser-Gly-Asn- Asn-Arg-Xaa₁-Xaa₄-Cys-Arg-Xaa₁-Ser; (SEQ ID NO: 210) Asp-Xaa₅-Cys-Cys-Ser-Xaa₄-Xaa₅-Asp-Cys-Gly-Ala- Asn-His-Xaa₅-Xaa₁-Ile-Cys-Gly; (SEQ ID NO: 211) Xaa₁-Cys-Cys-Ser-Gln-Xaa₅-Xaa₅-Cys-Arg-Xaa₃- Xaa₂-His-Xaa₅-Xaa₁-Leu-Cys-Ser; (SEQ ID NO: 212) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ala-Gly-Asn- Asn-Xaa₅-His-Ile-Cys; (SEQ ID NO: 213) Gly-Cys-Cys-Ser-Asp-Xaa₅-Ser-Cys-Asn-Val-Asn- Asn-Xaa₅-Asp-Xaa₄-Cys; (SEQ ID NO: 214) Xaa₁-Xaa₁-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-Ser-Val- Gly-His-Gln-Asp-Met-Cys-Arg; (SEQ ID NO: 215) Gly-Gly-Cys-Cys-Ser-Asn-Xaa₅-Ala-Cys-Leu-Val- Asn-His-Leu-Xaa₁-Met-Cys; (SEQ ID NO: 216) Arg-Asp-Xaa₅-Cys-Cys-Phe-Asn-Xaa₅-Ala-Cys-Asn- Val-Asn-Asn-Xaa₅-Gln-Ile-Cys; (SEQ ID NO: 217) Cys-Cys-Ser-Asp-Xaa₅-Ser-Cys-Xaa₃-Arg-Leu-His- Ser-Leu-Ala-Cys-Thr-Gly-Ile-Val-Asn-Arg; (SEQ ID NO: 218) Cys-Cys-Thr-Asn-Xaa₅-Ala-Cys-Leu-Val-Asn-Asn- Ile-Arg-Phe-Cys-Gly; (SEQ ID NO: 219) Asp-Xaa₁-Cys-Cys-Ser-Asp-Xaa₅-Arg-Cys-His-Gly- Asn-Asn-Arg-Asp-His-Cys-Ala; (SEQ ID NO: 220) Asp-Cys-Cys-Ser-His-Xaa₅-Leu-Cys-Arg-Leu-Phe- Val-Xaa₅-Gly-Leu-Cys-Ile; (SEQ ID NO: 221) Gly-Cys-Cys-Ser-His-Xaa₅-Val-Cys-Xaa₂-Val-Arg- Xaa₄-Xaa₅-Asp-Leu-Cys-Arg; (SEQ ID NO: 222) Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val-Asn- Asn-Xaa₅-His-Ile-Cys; (SEQ ID NO: 223) Gly-Cys-Cys-Ser-His-Xaa₅-Val-Cys-Xaa₂-Val-Arg- Xaa₄-Ser-Asp-Met-Cys; (SEQ ID NO: 224) Gly-Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Xaa₂-Val- His-Phe-Xaa₅-His-Ser-Cys; (SEQ ID NO: 225) Val-Cys-Cys-Ser-Asn-Xaa₅-Val-Cys-His-Val-Asp- His-Xaa₅-Xaa₁-Leu-Cys-Arg-Arg-Arg-Arg; (SEQ ID NO: 226) Gly-Cys-Cys-Ser-His-Xaa₅-Val-Cys-Asn-Leu-Ser- Asn-Xaa₅-Gln-Ile-Cys-Arg; (SEQ ID NO: 227) Xaa₆-Xaa₁-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Asn-Val- Asp-His-Xaa₅-Xaa₁-Ile-Cys-Arg; (SEQ ID NO: 228) Gly-Cys-Cys-Ser-Asn-Xaa₅-Ala-Cys-Leu-Val-Asn- His-Ile-Arg-Phe-Cys-Gly; (SEQ ID NO: 229) Asp-Cys-Cys-Asp-Asp-Xaa₅-Ala-Cys-Thr-Val-Asn- Asn-Xaa₅-Gly-Leu-Cys-Thr; and (SEQ ID NO: 230) Gly-Cys-Cys-Ser-Asn-Xaa₅-Xaa₅-Cys-Ile-Ala- Xaa₂-Asn-Xaa₅-His-Met-Cys-Gly-Gly-Arg-Arg, wherein Xaa₁ is Glu or γ-carboxy-Glu (Gla); Xaa₂ is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa₃ is Trp (D or L), halo-Trp or neo-Trp; Xaa₄ is Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; and Xaa₅ is Pro or hydroxy-Pro; Xaa₆ is Gln or pyro-Glu; and the C-terminus contains a carboxyl or amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for Tyr and bromine for Trp. In addition, the His residues may be substituted with halo-His; the Arg residues may be substituted by Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Tyr residues may be substituted with any unnatural hydroxy containing amino acid; the Ser residues may be substituted with Thr; the Thr residues may be substituted with Ser; and the Phe and Trp residues may be substituted with any unnatural aromatic amino acid. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.

More specifically, the present invention is directed to the following α-conotoxin peptides of general formula III:

SmI: SEQ ID NO: 22, wherein Xaa₁ is Glu and Xaa₅ is Pro; OB-29: SEQ ID NO: 23, wherein Xaa₁ is Glu, Xaa₃ is Tyr and Xaa₅ is Pro; Tx1.1: SEQ ID NO: 24, wherein Xaa₁ is Glu and Xaa₅ is Pro; R1.1A: SEQ ID NO: 25, wherein Xaa₁ is Glu and Xaa₅ is Pro; R1.1B: SEQ ID NO: 26, wherein Xaa₁ is Glu and Xaa₅ is Pro; Om-9: SEQ ID NO: 27, wherein Xaa₁ is Glu and Xaa₅ is Pro; Om-10: SEQ ID NO: 28, wherein Xaa₅ is Pro; Om-21: SEQ ID NO: 29, wherein Xaa₁ is Glu and Xaa₅ is Pro; Om-25: SEQ ID NO: 30, wherein Xaa₁ is Glu and Xaa₅ is Pro; Om-27: SEQ ID NO: 31, wherein Xaa₁ is Glu and Xaa₅ is Pro; Om-28: SEQ ID NO: 32, wherein Xaa₁ is Glu and Xaa₅ is Pro; Bt1.2: SEQ ID NO: 33, wherein Xaa₁ is Glu and Xaa₅ is Pro; Bt1.4: SEQ ID NO: 34, wherein Xaa₁ is Glu and Xaa₅ is Pro; Da1.1: SEQ ID NO: 35, wherein Xaa₁ is Glu and Xaa₅ is Pro; OB-20: SEQ ID NO: 36, wherein Xaa₁ is Glu, Xaa₂ is Lys and Xaa₅ is Pro; TI: SEQ ID NO: 37, wherein Xaa₁ is Glu and Xaa₅ is Pro; TIB: SEQ ID NO: 38, wherein Xaa₁ is Glu and Xaa₅ is Pro; Pn1.1: SEQ ID NO: 39, wherein Xaa₅ is Pro; Pn1.2: SEQ ID NO: 40, wherein Xaa₁ is Glu and Xaa₅ is Pro; T1: SEQ ID NO: 41, wherein Xaa₂ is Lys and Xaa₅ is Pro; TIA: SEQ ID NO: 43, wherein Xaa₅ is Pro; Da1.2: SEQ ID NO: 44, wherein Xaa₅ is Pro; Cr1.2: SEQ ID NO: 45, wherein Xaa₁ is Glu and Xaa₅ is Pro; Sl1.2: SEQ ID NO: 46, wherein Xaa₁ is Glu, Xaa₂ is Lys and Xaa₅ is Pro; Tx1.3: SEQ ID NO: 47, wherein Xaa₁ is Glu and Xaa₅ is Pro; Da1.3: SEQ ID NO: 48, wherein Xaa₁ is Glu and Xaa₅ is Pro; Da1.4: SEQ ID NO: 49, wherein Xaa₁ is Glu, Xaa₅ is Pro and Xaa₆ is Gln; Tx1.2: SEQ ID NO: 50, wherein Xaa₅ is Pro; Om-35: SEQ ID NO: 51, wherein Xaa₁ is Glu and Xaa₅ is Pro; Sl1.1: SEQ ID NO: 52, wherein Xaa₁ is Glu, Xaa₃ is Trp, Xaa₄ is Tyr and Xaa₅ is Pro; Sl1.6: SEQ ID NO: 53, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Sl1.7: SEQ ID NO: 54, wherein Xaa₁ is Glu Xaa₄ is Tyr and Xaa₅ is Pro; Bt1.1: SEQ ID NO: 55, wherein Xaa₁ is Glu Xaa₄ is Tyr and Xaa₅ is Pro; Bt: 1.3: SEQ ID NO: 56, wherein Xaa₁ is Glu Xaa₄ is Tyr and Xaa₅ is Pro; Bt1.5: SEQ ID NO: 57, wherein Xaa₁ is Glu Xaa₄ is Tyr and Xaa₅ is Pro; A1.4: SEQ ID NO: 170, wherein Xaa₁ is Glu and Xaa₅ is Pro; A1.5: SEQ ID NO: 171, wherein Xaa₁ is Glu and Xaa₅ is Pro; A1.6: SEQ ID NO: 172, wherein Xaa₁ is Glu and Xaa₅ is Pro; Af1.1: SEQ ID NO: 173, wherein Xaa₁ is Glu Xaa₄ is Tyr, Xaa₅ is Pro and Xaa₆ is Gln; Af1.2: SEQ ID NO: 174, wherein Xaa₁ is Glu and Xaa₅ is Pro; Ar1.2: SEQ ID NO: 175, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₃ is Trp, Xaa₄ is Try and Xaa₅ is Pro; Ar1.3: SEQ ID NO: 176, wherein Xaa₁ is Glu, Xaa₄ is Tyr and Xaa₅ is Pro; Ar1.4: SEQ ID NO: 177, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₃ is Trp, Xaa₄ is Try and Xaa₅ is Pro; Ar1.5: SEQ ID NO: 178, wherein Xaa₁ is Glu and Xaa₅ is Pro; Ar1.6: SEQ ID NO: 179, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₃ is Trp, Xaa₄ is Try and Xaa₅ is Pro; Ay1.2: SEQ ID NO: 180, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Ay1.3: SEQ ID NO: 181, wherein Xaa₅ is Pro; Bn1.4: SEQ ID NO: 182, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Bt1.8: SEQ ID NO: 183, wherein Xaa₁ is Glu and Xaa₅ is Pro; Bt1.9: SEQ ID NO: 184, wherein Xaa₁ is Glu, Xaa₄ is Tyr and Xaa₅ is Pro; Ca1.3: SEQ ID NO: 185, wherein Xaa₁ is Glu, Xaa₃ is Trp, Xaa₄ is Try and Xaa₅ is Pro; Ca1.4: SEQ ID NO: 186, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₃ is Trp, Xaa₄ is Try, Xaa₅ is Pro and Xaa₆ is Gln; C1.2: SEQ ID NO: 187, wherein Xaa₁ is Glu and Xaa₅ is Pro; C1.3: SEQ ID NO: 188, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Ep1.2: SEQ ID NO: 189, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₃ is Trp and Xaa₅ is Pro; G1.1: SEQ ID NO: 190, wherein Xaa₅ is Pro; G1.3: SEQ ID NO: 191, wherein Xaa₅ is Pro; Im1.3: SEQ ID NO: 192, wherein Xaa₅ is Pro; Lv1.2: SEQ ID NO: 193, wherein Xaa₁ is Glu and Xaa₅ is Pro; Lv1.3: SEQ ID NO: 194, wherein Xaa₂ is Lys and Xaa₅ is Pro; Lv1.4: SEQ ID NO: 195, wherein Xaa₁ is Glu and Xaa₅ is Pro; Lv1.6: SEQ ID NO: 196, wherein Xaa₅ is Pro; Lv1.7: SEQ ID NO: 197, wherein Xaa₁ is Glu and Xaa₅ is Pro; Lv1.8: SEQ ID NO: 198, wherein Xaa₅ is Pro; Lv1.9: SEQ ID NO: 199, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Lv1.10: SEQ ID NO: 200, wherein Xaa₁ is Glu; Mr1.3: SEQ ID NO: 201, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Mr1.4: SEQ ID NO: 202, wherein Xaa₅ is Pro; Ms1.1: SEQ ID NO: 203, wherein Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Ms1.6: SEQ ID NO: 204, wherein Xaa₄ is Tyr and Xaa₅ is Pro; O1.1: SEQ ID NO: 205, wherein Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; O1.2: SEQ ID NO: 206, wherein Xaa₁ is Glu, Xaa₄ is Tyr and Xaa₅ is Pro; O1.4: SEQ ID NO: 207, wherein Xaa₁ is Glu, Xaa₃ is Trp, Xaa₄ is Tyr and Xaa₅ is Pro; O1.7: SEQ ID NO: 208, wherein Xaa₄ is Tyr and Xaa₅ is Pro; O1.8: SEQ ID NO: 209, wherein Xaa₁ is Glu, Xaa₄ is Tyr and Xaa₅ is Pro; Om1.2: SEQ ID NO: 210, wherein Xaa₁ is Glu, Xaa₄ is Tyr and Xaa₅ is Pro; Om1.3: SEQ ID NO: 211, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₃ is Trp and Xaa₅ is Pro; Om1.4: SEQ ID NO: 212, wherein Xaa₅ is Pro; Om1.5: SEQ ID NO: 213, wherein Xaa₄ is Tyr and Xaa₅ is Pro; Om1.6: SEQ ID NO: 214, wherein Xaa₁ is Glu and Xaa₅ is Pro; P1.4: SEQ ID NO: 215, wherein Xaa₁ is Glu and Xaa₅ is Pro; P1.5: SEQ ID NO: 216, wherein Xaa₅ is Pro; P1.6: SEQ ID NO: 217, wherein Xaa₃ is Trp and Xaa₅ is Pro; P1.8: SEQ ID NO: 218, wherein Xaa₅ is Pro; Rg1.1: SEQ ID NO: 219, wherein Xaa₁ is Glu and Xaa₅ is Pro; Rg1.3: SEQ ID NO: 220, wherein Xaa₅ is Pro; Rg1.4: SEQ ID NO: 221, wherein Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Rg1.5: SEQ ID NO: 222, wherein Xaa₅ is Pro; Rg1.8: SEQ ID NO: 223, wherein Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; Sm1.4: SEQ ID NO: 224, wherein Xaa₂ is Lys and Xaa₅ is Pro; Sm1.5: SEQ ID NO: 225, wherein Xaa₁ is Glu and Xaa₅ is Pro; S1.5: SEQ ID NO: 226, wherein Xaa₅ is Pro; Tx1.5: SEQ ID NO: 227, wherein Xaa₁ is Glu, Xaa₅ is Pro and Xaa₆ is Gln; T1.1: SEQ ID NO: 228, wherein Xaa₅ is Pro; Vr1.3: SEQ ID NO: 229, wherein Xaa₅ is Pro; and Tb: SEQ ID NO: 230, wherein Xaa₂ is Lys and Xaa₅ is Pro. The C-terminus preferably contains a carboxyl group for the peptides OB-29, Tx1.1, R1.1A, R1.1B, Om-9, Om-10, Om-21, Om-25, Om-27, Om-28, Cr1.2, Om-35, Bt1.1, Bt1.3, Bt1.5, A1.4, A1.6, Ar1.2, Ar1.3, Ar1.4, Ar1.5, Ar1.6, Ca1.3, Ca1.4, Ep1.2, Lv1.9, O1.2, Om1.3, Om1.6, P1.6, Rg1.1, Rg1.3, Rg1.4, Sm1.5, Tx1.5 and Vr1.3. The C-terminus of the other peptides preferably contains an amide group.

The present invention is also directed to the novel specific α-conotoxin peptides having the formulas:

(SEQ ID NO: 231) Cys-Cys-Thr-Ile-Xaa₅-Ser-Cys-Xaa₄-Xaa₁-Xaa₂-Xaa₂- Xaa₂-Ile-Xaa₂-Ala-Cys-Val-Phe and (SEQ ID NO: 232) Gly-Cys-Cys-Gly-Asn-Xaa₅-Ala-Cys-Ser-Gly-Ser- Ser-Xaa₂-Asp-Ala-Xaa₅-Ser-Cys, wherein Xaa₁ is Glu or γ-carboxy-Glu (Gla); Xaa₂ is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa₄ is Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; and Xaa₅ is Pro or hydroxy-Pro; and the C-terminus contains a carboxyl or amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for Tyr. In addition, the His residues may be substituted with halo-His; the Arg residues may be substituted by Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Tyr residues may be substituted with any unnatural hydroxy containing amino acid; the Ser residues may be substituted with Thr; the Thr residues may be substituted with Ser; and the Phe residues may be substituted with any unnatural aromatic amino acid. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.

More specifically, the present invention is directed to the following α-conotoxin peptides:

G1.2: SEQ ID NO: 231, wherein Xaa₁ is Glu, Xaa₂ is Lys, Xaa₄ is Tyr and Xaa₅ is Pro; and Rg1.12: SEQ ID NO: 232, wherein Xaa₂ is Lys and Xaa₅ is Pro. The C-terminus of G1.2 preferably contains a carboxyl group, and the C-terminus of Rg1.12 preferably contains an amide group.

Examples of unnatural aromatic amino acid include, but are not limited to, such as nitro-Phe, 4-substituted-Phe wherein the substituent is C₁-C₃ alkyl, carboxyl, hydroxymethyl, sulphomethyl, halo, phenyl, —CHO, —CN, —SO₃H and —NHAc. Examples of unnatural hydroxy containing amino acid, include, but are not limited to, such as 4-hydroxymethyl-Phe, 4-hydroxyphenyl-Gly, 2,6-dimethyl-Tyr and 5-amino-Tyr. Examples of unnatural basic amino acids include, but are not limited to, N-1-(2-pyrazolinyl)-Arg, 2-(4-piperinyl)-Gly, 2-(4-piperinyl)-Ala, 2-[3-(2S)pyrrolininyl)-Gly and 2-[3-(2S)pyrrolininyl)-Ala. These and other unnatural basic amino acids, unnatural hydroxy containing amino acids or unnatural aromatic amino acids are described in Building Block Index, Version 3.0 (1999 Catalog, pages 4-47 for hydroxy containing amino acids and aromatic amino acids and pages 66-87 for basic amino acids; see also website “amino-acids.com”), incorporated herein by reference, by and available from RSP Amino Acid Analogues, Inc., Worcester, Mass.

Optionally, in the peptides of general formulas I, II and III and the specific peptides described above, the Asn residues may be modified to contain an N-glycan and the Ser and Thr residues may be modified to contain an O-glycan. In accordance with the present invention, a glycan shall mean any N-, S- or O-linked mono-, di-, tri-, poly- or oligosaccharide that can be attached to any hydroxy, amino or thiol group of natural or modified amino acids by synthetic or enzymatic methodologies known in the art. The monosaccharides making up the glycan can include D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-galactosamine, D-glucosamine, D-N-acetyl-glucosamine (GlcNAc), D-N-acetyl-galactosamine (GalNAc), D-fucose or D-arabinose. These saccharides may be structurally modified, e.g., with one or more O-sulfate, O-phosphate, O-acetyl or acidic groups, such as sialic acid, including combinations thereof. The glycan may also include similar polyhydroxy groups, such as D-penicillamine 2,5 and halogenated derivatives thereof or polypropylene glycol derivatives. The glycosidic linkage is beta and 1-4 or 1-3, preferably 1-3. The linkage between the glycan and the amino acid may be alpha or beta, preferably alpha and is 1-.

Core O-glycans have been described by Van de Steen et al. (1998), incorporated herein by reference. Mucin type O-linked oligosaccharides are attached to Ser or Thr (or other hydroxylated residues of the present peptides) by a GalNAc residue. The monosaccharide building blocks and the linkage attached to this first GalNAc residue define the “core glycans,” of which eight have been identified. The type of glycosidic linkage (orientation and connectivities) are defined for each core glycan. Suitable glycans and glycan analogs are described further in U.S. Ser. No. 09/420,797, filed 19 Oct. 1999 (now U.S. Pat. No. 6,369,193) and in PCT Application No. PCT/US99/24380, filed 19 Oct. 1999, both incorporated herein by reference. A preferred glycan is Gal(β1→3)GalNAc(α1→).

Optionally, in the peptides of general formulas I and II and the specific peptides described above, pairs of Cys residues may be replaced pairwise with Ser/(Glu or Asp) or Lys/(Glu or Asp) combinations. Sequential coupling by known methods (Barnay et al., 2000; Hruby et al., 1994; Bitan et al., 1997) allows replacement of native Cys bridges with lactam bridges.

The present invention is further directed to propeptides and nucleic acid sequences encoding the propeptides or peptides as described in further detail herein.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

The present invention, in another aspect, relates to a pharmaceutical composition comprising an effective amount of an α-conotoxin peptide. Such a pharmaceutical composition has the capability of acting as antagonists for nicotinic acetylcholine receptors. In one aspect, the α-conotoxins with specificity for neuromuscular junction nicotinic acetylcholine receptors are used as neuromuscular blocking agents for use in conjunction with surgery, as disclosed in U.S. patent application Ser. No. 09/488,799, filed 21 Jan. 2000, incorporated by reference herein. In a second aspect, additional α-conotoxins and uses for them have been described in U.S. Pat. Nos. 4,447,356 (Olivera et al., 1984); 5,432,155; 5,514,774, each incorporated herein by reference.

In a third aspect additional uses for α-conotoxins are described in U.S. Ser. No. 09/219,446, filed 22 Dec. 1998, incorporated herein by reference. In this application, α-conotoxins with specificity for neuronal nicotinic acetylcholine receptors are used for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma.

The α-conotoxin peptides described herein are sufficiently small to be chemically synthesized. General chemical syntheses for preparing the foregoing α-conotoxin peptides are described hereinafter. Various ones of the α-conotoxin peptides can also be obtained by isolation and purification from specific Conus species using the technique described in U.S. Pat. No. 4,447,356 (Olivera et al., 1984), the disclosure of which is incorporated herein by reference.

Although the α-conotoxin peptides of the present invention can be obtained by purification from cone snails, because the amounts of α-conotoxin peptides obtainable from individual snails are very small, the desired substantially pure α-conotoxin peptides are best practically obtained in commercially valuable amounts by chemical synthesis using solid-phase strategy. For example, the yield from a single cone snail may be about 10 micrograms or less of α-conotoxin peptide. By “substantially pure” is meant that the peptide is present in the substantial absence of other biological molecules of the same type; it is preferably present in an amount of at least about 85% purity and preferably at least about 95% purity. Chemical synthesis of biologically active α-conotoxin peptides depends of course upon correct determination of the amino acid sequence.

The α-conotoxin peptides can also be produced by recombinant DNA techniques well known in the art. Such techniques are described by Sambrook et al. (1989). The peptides produced in this manner are isolated, reduced if necessary, and oxidized to form the correct disulfide bonds.

One method of forming disulfide bonds in the conantokin peptides of the present invention is the air oxidation of the linear peptides for prolonged periods under cold room temperatures or at room temperature. This procedure results in the creation of a substantial amount of the bioactive, disulfide-linked peptides. The oxidized peptides are fractionated using reverse-phase high performance liquid chromatography (HPLC) or the like, to separate peptides having different linked configurations. Thereafter, either by comparing these fractions with the elution of the native material or by using a simple assay, the particular fraction having the correct linkage for maximum biological potency is easily determined. However, because of the dilution resulting from the presence of other fractions of less biopotency, a somewhat higher dosage may be required.

The peptides are synthesized by a suitable method, such as by exclusively solid-phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution couplings.

In conventional solution phase peptide synthesis, the peptide chain can be prepared by a series of coupling reactions in which constituent amino acids are added to the growing peptide chain in the desired sequence. Use of various coupling reagents, e.g., dicyclohexylcarbodiimide or diisopropylcarbonyldimidazole, various active esters, e.g., esters of N-hydroxyphthalimide or N-hydroxy-succinimide, and the various cleavage reagents, to carry out reaction in solution, with subsequent isolation and purification of intermediates, is well known classical peptide methodology. Classical solution synthesis is described in detail in the treatise, “Methoden der Organischen Chemie (Houben-Weyl): Synthese von Peptiden,” (1974). Techniques of exclusively solid-phase synthesis are set forth in the textbook, “Solid-Phase Peptide Synthesis,” (Stewart and Young, 1969), and are exemplified by the disclosure of U.S. Pat. No. 4,105,603 (Vale et al., 1978). The fragment condensation method of synthesis is exemplified in U.S. Pat. No. 3,972,859 (1976). Other available syntheses are exemplified by U.S. Pat. No. 3,842,067 (1974) and 3,862,925 (1975). The synthesis of peptides containing γ-carboxyglutamic acid residues is exemplified by Rivier et al. (1987), Nishiuchi et al. (1993) and Zhou et al. (1996).

Common to such chemical syntheses is the protection of the labile side chain groups of the various amino acid moieties with suitable protecting groups which will prevent a chemical reaction from occurring at that site until the group is ultimately removed. Usually also common is the protection of an α-amino group on an amino acid or a fragment while that entity reacts at the carboxyl group, followed by the selective removal of the α-amino protecting group to allow subsequent reaction to take place at that location. Accordingly, it is common that, as a step in such a synthesis, an intermediate compound is produced which includes each of the amino acid residues located in its desired sequence in the peptide chain with appropriate side-chain protecting groups linked to various ones of the residues having labile side chains.

As far as the selection of a side chain amino protecting group is concerned, generally one is chosen which is not removed during deprotection of the α-amino groups during the synthesis. However, for some amino acids, e.g., His, protection is not generally necessary. In selecting a particular side chain protecting group to be used in the synthesis of the peptides, the following general rules are followed: (a) the protecting group preferably retains its protecting properties and is not split off under coupling conditions, (b) the protecting group should be stable under the reaction conditions selected for removing the α-amino protecting group at each step of the synthesis, and (c) the side chain protecting group must be removable, upon the completion of the synthesis containing the desired amino acid sequence, under reaction conditions that will not undesirably alter the peptide chain.

It should be possible to prepare many, or even all, of these peptides using recombinant DNA technology. However, when peptides are not so prepared, they are preferably prepared using the Merrifield solid-phase synthesis, although other equivalent chemical syntheses known in the art can also be used as previously mentioned. Solid-phase synthesis is commenced from the C-terminus of the peptide by coupling a protected α-amino acid to a suitable resin. Such a starting material can be prepared by attaching an α-amino-protected amino acid by an ester linkage to a chloromethylated resin or a hydroxymethyl resin, or by an amide bond to a benzhydrylamine (BHA) resin or paramethylbenzhydrylamine (MBHA) resin. Preparation of the hydroxymethyl resin is described by Bodansky et al. (1966). Chloromethylated resins are commercially available from Bio Rad Laboratories (Richmond, Calif.) and from Lab. Systems, Inc. The preparation of such a resin is described by Stewart and Young (1969). BHA and MBHA resin supports are commercially available, and are generally used when the desired polypeptide being synthesized has an unsubstituted amide at the C-terminus Thus, solid resin supports may be any of those known in the art, such as one having the formulae —O—CH₂-resin support, —NH BHA resin support, or —NH-MBHA resin support. When the unsubstituted amide is desired, use of a BHA or MBHA resin is preferred, because cleavage directly gives the amide. In case the N-methyl amide is desired, it can be generated from an N-methyl BHA resin. Should other substituted amides be desired, the teaching of U.S. Pat. No. 4,569,967 (Kornreich et al., 1986) can be used, or should still other groups than the free acid be desired at the C-terminus, it may be preferable to synthesize the peptide using classical methods as set forth in the Houben-Weyl text (1974).

The C-terminal amino acid, protected by Boc or Fmoc and by a side-chain protecting group, if appropriate, can be first coupled to a chloromethylated resin according to the procedure set forth in K. Horiki et al. (1978), using KF in DMF at about 60° C. for 24 hours with stirring, when a peptide having free acid at the C-terminus is to be synthesized. Following the coupling of the BOC-protected amino acid to the resin support, the α-amino protecting group is removed, as by using trifluoroacetic acid (TFA) in methylene chloride or TFA alone. The deprotection is carried out at a temperature between about 0° C. and room temperature. Other standard cleaving reagents, such as HCl in dioxane, and conditions for removal of specific α-amino protecting groups may be used as described in Schroder & Lubke (1965).

After removal of the α-amino-protecting group, the remaining α-amino- and side chain-protected amino acids are coupled step-wise in the desired order to obtain the intermediate compound defined hereinbefore, or as an alternative to adding each amino acid separately in the synthesis, some of them may be coupled to one another prior to addition to the solid phase reactor. Selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as a coupling reagent is N,N′-dicyclohexylcarbodiimide (DCC, DIC, HBTU, HATU, TBTU in the presence of HoBt or HoAt).

The activating reagents used in the solid phase synthesis of the peptides are well known in the peptide art. Examples of suitable activating reagents are carbodiimides, such as N,N′-diisopropylcarbodiimide and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide. Other activating reagents and their use in peptide coupling are described by Schroder & Lubke (1965) and Kapoor (1970).

Each protected amino acid or amino acid sequence is introduced into the solid-phase reactor in about a twofold or more excess, and the coupling may be carried out in a medium of dimethylformamide (DMF):CH₂Cl₂ (1:1) or in DMF or CH₂Cl₂ alone. In cases where intermediate coupling occurs, the coupling procedure is repeated before removal of the α-amino protecting group prior to the coupling of the next amino acid. The success of the coupling reaction at each stage of the synthesis, if performed manually, is preferably monitored by the ninhydrin reaction, as described by Kaiser et al. (1970). Coupling reactions can be performed automatically, as on a Beckman 990 automatic synthesizer, using a program such as that reported in Rivier et al. (1978).

After the desired amino acid sequence has been completed, the intermediate peptide can be removed from the resin support by treatment with a reagent, such as liquid hydrogen fluoride or TFA (if using Fmoc chemistry), which not only cleaves the peptide from the resin but also cleaves all remaining side chain protecting groups and also the α-amino protecting group at the N-terminus if it was not previously removed to obtain the peptide in the form of the free acid. If Met is present in the sequence, the Boc protecting group is preferably first removed using trifluoroacetic acid (TFA)/ethanedithiol prior to cleaving the peptide from the resin with HF to eliminate potential S-alkylation. When using hydrogen fluoride or TFA for cleaving, one or more scavengers such as anisole, cresol, dimethyl sulfide and methylethyl sulfide are included in the reaction vessel.

Cyclization of the linear peptide is preferably affected, as opposed to cyclizing the peptide while a part of the peptido-resin, to create bonds between Cys residues. To effect such a disulfide cyclizing linkage, fully protected peptide can be cleaved from a hydroxymethylated resin or a chloromethylated resin support by ammonolysis, as is well known in the art, to yield the fully protected amide intermediate, which is thereafter suitably cyclized and deprotected. Alternatively, deprotection, as well as cleavage of the peptide from the above resins or a benzhydrylamine (BHA) resin or a methylbenzhydrylamine (MBHA), can take place at 0° C. with hydrofluoric acid (HF) or TFA, followed by oxidation as described above.

The peptides are also synthesized using an automatic synthesizer. Amino acids are sequentially coupled to an MBHA Rink resin (typically 100 mg of resin) beginning at the C-terminus using an Advanced Chemtech 357 Automatic Peptide Synthesizer. Couplings are carried out using 1,3-diisopropylcarbodimide in N-methylpyrrolidinone (NMP) or by 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and diethyliso-propylethylamine (DIEA). The FMOC protecting group is removed by treatment with a 20% solution of piperidine in dimethylformamide(DMF). Resins are subsequently washed with DMF (twice), followed by methanol and NMP.

Pharmaceutical compositions containing a compound of the present invention or its pharmaceutically acceptable salts as the active ingredient can be prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa.). Typically, an antagonistic amount of the active ingredient will be admixed with a pharmaceutically acceptable carrier. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral. The compositions may further contain antioxidizing agents, stabilizing agents, preservatives and the like.

For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, suspensions or emulsions. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. The active agent can be encapsulated to make it stable to passage through the gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, WO 96/11698.

For parenteral administration, the compound may be dissolved in a pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid.

The active agent is preferably administered in an therapeutically effective amount. The actual amount administered, and the rate and time-course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc., is within the responsibility of general practitioners or specialists, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's Pharmaceutical Sciences. Typically the conopeptides of the present invention exhibit their effect at a dosage range from about 0.001 mg/kg to about 250 mg/kg, preferably from about 0.05 mg/kg to about 100 mg/kg of the active ingredient, more preferably from a bout 0.1 mg/kg to about 75 mg/kg. A suitable dose can be administered in multiple sub-doses per day. Typically, a dose or sub-dose may contain from about 0.1 mg to about 500 mg of the active ingredient per unit dosage form. A more preferred dosage will contain from about 0.5 mg to about 100 mg of active ingredient per unit dosage form. Dosages are generally initiated at lower levels and increased until desired effects are achieved.

Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands. Targeting may be desirable for a variety of reasons, e.g. if the agent is unacceptably toxic, or if it would otherwise require too high a dosage, or if it would not otherwise be able to enter the target cells.

The active agents, which are peptides, can also be administered in a cell based delivery system in which a DNA sequence encoding an active agent is introduced into cells designed for implantation in the body of the patient, especially in the spinal cord region. Suitable delivery systems are described in U.S. Pat. No. 5,550,050 and published PCT Application Nos. WO 92/19195, WO 94/25503, WO 95/01203, WO 95/05452, WO 96/02286, WO 96/02646, WO 96/40871, WO 96/40959 and WO 97/12635. Suitable DNA sequences can be prepared synthetically for each active agent on the basis of the developed sequences and the known genetic code.

EXAMPLES

The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized.

Example 1 Isolation of α-Conotoxins

Crude venom was extracted from venom ducts (Cruz et al., 1976), and the components were purified as previously described (Cartier et al., 1996a). The crude extract from venom ducts was purified by reverse phase liquid chromatography (RPLC) using a Vydac C₁₈ semi-preparative column (10×250 mm) and elution with a linear gradient of acetonitrile in 0.1% TFA. Further purification of bioactive peaks was done on a Vydac C₁₈ analytical column (4.6×220 mm) eluted with a gradient of acetonitrile in 0.1% TFA. The effluents were monitored at 220 nm. Peaks were collected, and aliquots were assayed for activity. Activity was monitored by assessing block of α3β4 nAChRs expressed in Xenopus oocytes.

The amino acid sequence of the purified peptides were determined by standard methods. The purified peptides were reduced and alkylated prior to sequencing by automated Edman degradation on an Applied Biosystems 477A Protein Sequencer with a 120A Analyzer (DNA/Peptide Facility, University of Utah) (Martinez et al., 1995; Shon et al., 1994).

In accordance with this method, peptides MII, AuIA, AuIB, AuIC, MAR-1, MAR-2, TI, OB-29, EpI, S1.1, Bn1.1, Bn1.2, Ca1.1, Ca1.2, Cn1.1, Cn1.2 and Sm1.3 were obtained.

Example 2 Synthesis of Conopeptides

The synthesis of conopeptides, either the mature toxins or the precursor peptides, was separately performed using conventional protection chemistry as described by Cartier et al. (1996). Briefly, the linear chains were built on Rink amide resin by Fmoc procedures with 2-(1H-benzotriol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborated coupling using an ABI model 430A peptide synthesizer with amino acid derivatives purchased from Bachem (Torrance Calif.). Orthogonal protection was used on cysteines: Cys³ and Cys¹⁶ were protected as the stable Cys(S-acetamidomethyl), while Cys² and Cys⁸ were protected as the acid-labile Cys(S-trityl). After removal of the terminal Fmoc protecting group and cleavage of the peptides from the resins, the released peptides were precipitated by filtering the reaction mixture into −10° C. methyl t-butyl ether, which removed the protecting groups except on Cys³ and Cys¹⁶. The peptides were dissolved in 0.1% TFA and 60% acetonitrile and purified by RPLC on a Vydac C₁₈ preparative column (22×250 mm) and eluted at a flow rate of 20 mL/min with a gradient of acetonitrile in 0.1% TFA.

The disulfide bridges in the three conopeptides were formed as described in Cartier et al. (1996). Briefly, the disulfide bridges between Cys² and Cys⁸ were formed by air oxidation which was judged to be complete by analytical RPLC. The monocyclic peptides were purified by RPLC on a Vydac C₁₈ preparative column (22×250 mm) and eluted with a gradient of acetonitrile in 0.1% TFA. Removal of S-acetamidomethyl groups and closure of the disulfide bridge between Cys³ and Cys¹⁶ was carried out simultaneously be iodine oxidation. The cyclic peptides were purified by RPLC on a Vydac C₁₈ preparative column (22×250 mm) and eluted with a gradient of acetonitrile in 0.1% TFA.

Example 3 Isolation of DNA Encoding α-Conotoxins

DNA coding for α-conotoxins was isolated and cloned in accordance with conventional techniques using general procedures well known in the art, such as described in Olivera et al. (1996). Alternatively, cDNA libraries was prepared from Conus venom duct using conventional techniques. DNA from single clones was amplified by conventional techniques using primers which correspond approximately to the M13 universal priming site and the M13 reverse universal priming site. Clones having a size of approximately 300 nucleotides were sequenced and screened for similarity in sequence to known α-conotoxins. The DNA sequences and encoded propeptide or peptide sequences are set forth in Tables 1-134.

TABLE 1 DNA Sequence (SEQ ID NO: 58) and Protein Sequence (SEQ ID NO: 59) of MII atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc Thr Val Val Ser ttc cct tca gat cgt gca tct gat ggc agg aat gcc Phe Pro Ser Asp Arg Ala Ser Asp Gly Arg Asn Ala gca gcc aac gac Ala Ala Asn Asp aaa gcg tct gac gtg atc acg ctg gcc ctc aag gga Lys Ala Ser Asp Val Ile Thr Leu Ala Leu Lys Gly tgc tgt tcc aac Cys Cys Ser Asn cct gtc tgt cac ttg gag cat tca aac ctt tgt ggt Pro Val Cys His Leu Glu His Ser Asn Leu Cys Gly aga aga cgc Arg Arg Arg tgatgctcca ggaccctctg aaccacgacg ttcgagca

TABLE 2 DNA Sequence (SEQ ID NO: 60) and Protein Sequence (SEQ ID NO: 61) of AuIA atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc Thr Val Val Ser ttc act tca gat cgt gca tct gat ggc agg aag gac Phe Thr Ser Asp Arg Ala Ser Asp Gly Arg Lys Asp gca gcg tct ggc Ala Ala Ser Gly ctg atc gct ctg acc atc aag gga tgc tgt tct tat Leu Ile Ala Leu Thr Ile Lys Gly Cys Cys Ser Tyr cct ccc tgt ttc Pro Pro Cys Phe gcg act aat tca gac tat tgt ggt tgacgacgct Ala Thr Asn Ser Asp Tyr Cys Gly gatgctccag gaccctctga accacgacgt

TABLE 3 DNA Sequence (SEQ ID NO: 62) and Protein Sequence (SEQ ID NO: 63) of AuIB atg ttc acc gtg ttt ctg ttg gtc gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc Thr Val Val Ser ttc act tca gat cgt gca tct gat ggc agg aag gac Phe Thr Ser Asp Arg Ala Ser Asp Gly Arg Lys Asp gca gcg tct ggc Ala Ala Ser Gly ctg att gct ctg acc atg aag gga tgc tgt tct tat Leu Ile Ala Leu Thr Met Lys Gly Cys Cys Ser Tyr cct ccc tgt ttc Pro Pro Cys Phe gcg act aat cca gac tgt ggt cga cga cgc Ala Thr Asn Pro Asp Cys Gly Arg Arg Arg tgatgctcca ggaccctctg aaccacgacg t

TABLE 4  DNA Sequence (SEQ ID NO: 64) and Protein Sequence (SEQ ID NO: 65) of Tx1.3 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc tct tca ggt cgt agt aca ttt Thr Val Val Ser Phe Ser Ser Gly Arg Ser Thr Phe cgt ggc agg aat gcc gca gcc aaa gcg tct ggc ctg Arg Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu gtc agt ctg act gac agg aga cca gaa tgc tgt agt Val Ser Leu Thr Asp Arg Arg Pro Glu Cys Cys Ser gat cct cgc tgt aac tcg agt cat cca gaa ctt tgt Asp Pro Arg Cys Asn Ser Ser His Pro Glu Leu Cys ggt gga aga cgc tgatgctcca ggaccctctg aaccacgacg t Gly Gly Arg Arg

TABLE 5 DNA Sequence (SEQ ID NO: 66) and Protein Sequence (SEQ ID NO: 67) of Tx1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr gcc gtc gtt tcc ttc act tca gat cgt gca tct gat Ala Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp gac ggg aaa gcc get gcg tct gac ctg atc act ctg Asp Gly Lys Ala Ala Ala Ser Asp Leu Ile Thr Leu acc atc aag gga tgc tgt tct cgt cct ccc tgt atc Thr Ile Lys Gly Cys Cys Ser Arg Pro Pro Cys Ile gcg aat aat cca gac ttg tgt ggt tgacgacgct Ala Asn Asn Pro Asp Leu Cys Gly gatgctccag aacggtctga accacgacgt tcgagcaatg  ttcaccgtgt ttctgttggt tgtctt

TABLE 6 DNA Sequence (SEQ ID NO: 68) and Protein Sequence (SEQ ID NO: 69) of Tx1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc act tca ggt cgt agt aca ttt Thr Val Val Ser Phe Thr Ser Gly Arg Ser Thr Phe cgt ggc agg aat gcc gca gcc aaa gcg tct ggc ctg Arg Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu gtc agt ctg act gac agg aga cca caa tgc tgt tct Val Ser Leu Thr Asp Arg Arg Pro Gln Cys Cys Ser cat cct gcc tgt aac gta gat cat cca gaa att tgt His Pro Ala Cys Asn Val Asp His Pro Glu Ile Cys cgt tgaagacgct gatgctccag gaccctctga accacgacgt Arg

TABLE 7 DNA Sequence (SEQ ID NO: 70) and Protein Sequence (SEQ ID NO: 71) of R1.1A atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc act tca ggt cgt cgt aca ttt Thr Val Val Ser Phe Thr Ser Gly Arg Arg Thr Phe cat ggc agg aat gcc gca gcc aaa gcg tct ggc ctg His Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu gtc agt ctg act gac agg aga cca gaa tgc tgt tct Val Ser Leu Thr Asp Arg Arg Pro Glu Cys Cys Ser cat cct gcc tgt aac gta gat cat cca gaa att tgt His Pro Ala Cys Asn Val Asp His Pro Glu Ile Cys cgt tgaagacgct gatgctccag gaccctctga accacgacgt Arg

TABLE 8 DNA Sequence (SEQ ID NO: 72) and Protein Sequence (SEQ ID NO: 73) of R1.1B atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc act tca ggt cgt agt aca ttt Thr Val Val Ser Phe Thr Ser Gly Arg Ser Thr Phe cgt ggc agg aat gcc gca gcc aaa gcg tct ggc ctg Arg Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu gtc agt ctg act gac agg aga cca caa tgc tgt tct Val Ser Leu Thr Asp Arg Arg Pro Gln Cys Cys Ser cat cct gcc tgt aac gta gat cat cca gaa att tgc His Pro Ala Cys Asn Val Asp His Pro Glu Ile Cys gat tgaagacgct gatgctccag gaccctctga accacgacgt Asp

TABLE 9 DNA Sequence (SEQ ID NO: 74) and Protein Sequence (SEQ ID NO: 75) of S1.1 atg ttc act gtg ttt ctg ttg gtt gtc ttg gca atc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Ile act gtc gtt tcc ttc cct tta gat cgt gaa tct gat Thr Val Val Ser Phe Pro Leu Asp Arg Glu Ser Asp ggc gcg aat gcc gaa gcc cgc acc cac gat cat gag Gly Ala Asn Ala Glu Ala Arg Thr His Asp His Glu aag cac gca ctg gac cgg aat gga tgc tgt agg aat Lys His Ala Leu Asp Arg Asn Gly Cys Cys Arg Asn cct gcc tgt gag agc cac aga tgt ggt tgacgacgct Pro Ala Cys Glu Ser His Arg Cys Gly gatgctccag gaccctctga accacgacgt tcgagca

TABLE 10  DNA Sequence (SEQ ID NO: 76) and Protein Sequence (SEQ ID NO: 77) of Bn1.1 atg ttc acc atg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Met Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc gct tca gat cgt gca tct gat Thr Val Val Ser Phe Ala Ser Asp Arg Ala Ser Asp ggc agg aat gcc gca gcc aag gac aaa gcg tct gac Gly Arg Asn Ala Ala Ala Lys Asp Lys Ala Ser Asp ctg gtc gct ctg acc gtc aag gga tgc tgt tct cat Leu Val Ala Leu Thr Val Lys Gly Cys Cys Ser His cct gcc tgt agc gtg aat aat cca gac att tgt ggt Pro Ala Cys Ser Val Asn Asn Pro Asp Ile Cys Gly tgaagacgct gatgctccag gaccctctga accacgacgt tcgagca

TABLE 11 DNA Sequence (SEQ ID NO: 78) and Protein Sequence (SEQ ID NO: 79) of Bn1.2 aaa gaa tgc tgt act cat cct gcc tgt cac gtg agt Lys Glu Cys Cys Thr His Pro Ala Cys His Val Ser cat cca gaa ctc tgt ggt tgaaaagcga cgtgacgctc His Pro Glu Leu Cys Gly caggaccctc tgaaccacga cgttcgagca

TABLE 12 DNA Sequence (SEQ ID NO: 80) and Protein Sequence (SEQ ID NO: 81) of Bn1.3 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca act Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr gct gtt ctt cca gtc act tta gat cgt gca tct gat Ala Val Leu Pro Val Thr Leu Asp Arg Ala Ser Asp gga agg aat gca gca gcc aac gcc aaa acg cct cgc Gly Arg Asn Ala Ala Ala Asn Ala Lys Thr Pro Arg ctg atc gcg cca ttc atc agg gat tat tgc tgt cat Leu Ile Ala Pro Phe Ile Arg Asp Tyr Cys Cys His aga ggt ccc tgt atg gta tgg tgt ggt tgaagccgct Arg Gly Pro Cys Met Val Trp Cys Gly gctgctccag gaccctctga accac

TABLE 13 DNA Sequence (SEQ ID NO: 82) and Protein Sequence (SEQ ID NO: 83) of Ca1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtg gtt tcc ttc act tca gat cgt gct tct gat Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp ggc agg aat gcc gca gcc aac gcg ttt gac ctg atc Gly Arg Asn Ala Ala Ala Asn Ala Phe Asp Leu Ile get ctg atc gcc agg caa aat tgc tgt agc att ccc Ala Leu Ile Ala Arg Gln Asn Cys Cys Ser Ile Pro agc tgt tgg gag aaa tat aaa tgt agt taa Ser Cys Trp Glu Lys Tyr Lys Cys Ser

TABLE 14 DNA Sequence (SEQ ID NO: 84) and Protein Sequence (SEQ ID NO: 85) of Ca1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtg gtt tcc ttc act tca gat cgt gcg tct gaa Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Glu ggc agg aat get gca gcc aag gac aaa gcg tct gac Gly Arg Asn Ala Ala Ala Lys Asp Lys Ala Ser Asp ctg gtg get ctg aca gtc agg gga tgc tgt gcc att Leu Val Ala Leu Thr Val Arg Gly Cys Cys Ala Ile cgt gaa tgt cgc ttg cag aat gca gcg tat tgt ggt Arg Glu Cys Arg Leu Gln Asn Ala Ala Tyr Cys Gly  gga ata tac tgatgctcca ggaccctctg aaccacgacg Gly Ile Tyr

TABLE 15 DNA Sequence (SEQ ID NO: 86) and Protein Sequence (SEQ ID NO: 87) of TIB atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc cct tca gat att gca act gag Thr Val Val Ser Phe Pro Ser Asp Ile Ala Thr Glu ggc agg aat gcc gca gcc aaa gcg ttt gac ctg ata Gly Arg Asn Ala Ala Ala Lys Ala Phe Asp Leu Ile tct tcg atc gtc aag aaa gga tgc tgt tcc cat cct Ser Ser Ile Val Lys Lys Gly Cys Cys Ser His Pro gcc tgt tcg ggg aat aat cca gaa ttt tgt cgt caa Ala Cys Ser Gly Asn Asn Pro Glu Phe Cys Arg Gln ggt cgc tgatgctcca ggaccctctg aaccacgacg t Gly Arg

TABLE 16 DNA Sequence (SEQ ID NO: 88) and Protein Sequence (SEQ ID NO: 89) of TIA atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc cct tca gat ata gca act gag Thr Val Val Ser Phe Pro Ser Asp Ile Ala Thr Glu ggc agg aat gcc gca gcc aaa gcg ttt gac ctg ata Gly Arg Asn Ala Ala Ala Lys Ala Phe Asp Leu Ile tct tcg atc gtc agg aaa gga tgc tgt tcc aat ccc Ser Ser Ile Val Arg Lys Gly Cys Cys Ser Asn Pro gcc tgt gcg ggg aat aat cca cat gtt tgt cgt caa Ala Cys Ala Gly Asn Asn Pro His Val Cys Arg Gln ggt cgc tgatgctcca ggaccctctg aaccacgacg t Gly Arg

TABLE 17 DNA Sequence (SEQ ID NO: 90) and Protein Sequence (SEQ ID NO: 91) of Sl1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc aat tca gat cgt gat cca gca Thr Val Val Ser Phe Asn Ser Asp Arg Asp Pro Ala tta ggt ggc agg aat gct gca gcc aaa gcg tct gac Leu Gly Gly Arg Asn Ala Ala Ala Lys Ala Ser Asp aag atc get tcg acc ctc aag aga aga gga tgc tgt Lys Ile Ala Ser Thr Leu Lys Arg Arg Gly Cys Cys tcg tat ttt gac tgt aga atg atg ttt cca gaa atg Ser Tyr Phe Asp Cys Arg Met Met Phe Pro Glu Met tgt ggt tgg cga ggc tgatgctcca ggaccctctg Cys Gly Trp Arg Gly aaccacgacg t

TABLE 18 DNA Sequence (SEQ ID NO: 92) and Protein Sequence (SEQ ID NO: 93) of Sl1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc aat tca gat cgt gat cca gca Thr Val Val Ser Phe Asn Ser Asp Arg Asp Pro Ala tta ggt ggc agg aat get gca gcc ata gcg tct gac Leu Gly Gly Arg Asn Ala Ala Ala Ile Ala Ser Asp aag atc gct tcg acc ctc agg aga gga gga tgc tgt Lys Ile Ala Ser Thr Leu Arg Arg Gly Gly Cys Cys tct ttt cct gcc tgt aga aag tat cgt cca gaa atg Ser Phe Pro Ala Cys Arg Lys Tyr Arg Pro Glu Met tgt ggt gga cga cgc tgatgctcca ggaccctctg Cys Gly Gly Arg Arg aaccacgacg t

TABLE 19 DNA Sequence (SEQ ID NO: 94) and Protein Sequence (SEQ ID NO: 95) of Sl1.3 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc act tca gat cat gaa tct gat Thr Val Val Ser Phe Thr Ser Asp His Glu Ser Asp cgc ggt gat gcc caa acc atc caa gaa gtg ttt gag Arg Gly Asp Ala Gln Thr Ile Gln Glu Val Phe Glu atg ttc gct ctg gac agc gat gga tgc tgt tgg cat Met Phe Ala Leu Asp Ser Asp Gly Cys Cys Trp His cct gct tgt ggc aga cac tat tgt ggt cga aga cgc Pro Ala Cys Gly Arg His Tyr Cys Gly Arg Arg Arg tgatgctcca ggaccctctg aaccacgacg t

TABLE 20 DNA Sequence (SEQ ID NO: 96) and  Protein Sequence (SEQ ID NO: 97) of Sl1.6 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc aat tca gat cgt gat cca gca Thr Val Val Ser Phe Asn Ser Asp Arg Asp Pro Ala tta ggt ggc agg aat gct gca gcc ata gcg tct gac Leu Gly Gly Arg Asn Ala Ala Ala Ile Ala Ser Asp aag atc gct tcg acc ctc agg aga gga gga tgc tgt Lys Ile Ala Ser Thr Leu Arg Arg Gly Gly Cys Cys tct ttt gct gcc tgt aga aag tat cgt cca gaa atg Ser Phe Ala Ala Cys Arg Lys Tyr Arg Pro Glu Met tgt ggt gga cga cgc tgatgct Cys Gly Gly Arg Arg

TABLE 21 DNA Sequence (SEQ ID NO: 98) and  Protein Sequence (SEQ ID NO: 99) of Sl1.7 atg ttc acc gtg ttt ctg ttg gtt ctc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Leu Leu Ala Thr acc gtc gtt tcc ttc aat tca gat cgt gca tta ggt Thr Val Val Ser Phe Asn Ser Asp Arg Ala Leu Gly ggc agg aat gct gca gcc aaa gcg tct gac aag atc Gly Arg Asn Ala Ala Ala Lys Ala Ser Asp Lys Ile ctt tcg aac ctc agg aga gga gga tgc tgt ttt cat Leu Ser Asn Leu Arg Arg Gly Gly Cys Cys Phe His cct gtc tgt tac atc aat ctt cta gaa atg tgt cgt Pro Val Cys Tyr Ile Asn Leu Leu Glu Met Cys Arg caa cga ggc tgatcgtcca ggaccctctg aaccacgacg t Gln Arg Gly

TABLE 22 DNA Sequence (SEQ ID NO: 100) and  Protein Sequence (SEQ ID NO: 101) of Cn1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttg aca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Thr Thr act gtc gtt tcc ttc cct tca gat agt gca tct gat Thr Val Val Ser Phe Pro Ser Asp Ser Ala Ser Asp gtc agg gat gac gaa gcc aaa gac gaa agg tct gac Val Arg Asp Asp Glu Ala Lys Asp Glu Arg Ser Asp atg tac aaa tcg aaa cgg aat gga cgc tgt tgc cat Met Tyr Lys Ser Lys Arg Asn Gly Arg Cys Cys His cct gcc tgt ggc aaa cac ttt agt tgt gga cgc  Pro Ala Cys Gly Lys His Phe Ser Cys Gly Arg tgatgctcca ggaccctctg aaccacgacg t

TABLE 23 DNA Sequence(SEQ ID NO: 102)and  Protein Sequence (SEQ ID NO: 103) of SmI atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc tcc cct tca gat cgt gca tct gat Thr Val Val Ser Ser Pro Ser Asp Arg Ala Ser Asp ggc agg aat gcc gca gcc aac gag aaa gcg tct gac Gly Arg Asn Ala Ala Ala Asn Glu Lys Ala Ser Asp gtg atc gcg ctg gcc ctc aag gga tgc tgt tcc aac Val Ile Ala Leu Ala Leu Lys Gly Cys Cys Ser Asn cct gtc tgt cac ctg gag cat tca aac atg tgt ggt Pro Val Cys His Leu Glu His Ser Asn Met Cys Gly aga aga cgc tgatgctcca ggaccctctg aaccacgacg Arg Arg Arg

TABLE 24 DNA Sequence (SEQ ID NO: 104) and  Protein Sequence (SEQ ID NO: 105) of Bt1.1 atg ttc tcc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Ser Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc tcc act tca ggt ggt gca tct ggt Thr Val Val Ser Ser Thr Ser Gly Gly Ala Ser Gly ggc agg aag gct gca gcc aaa gcg tct aac cgg atc Gly Arg Lys Ala Ala Ala Lys Ala Ser Asn Arg Ile gct ctg acc gtc agg agt gca aca tgc tgt aat tat Ala Leu Thr Val Arg Ser Ala Thr Cys Cys Asn Tyr cct ccc tgt tac gag act tat cca gaa agt tgt ctg Pro Pro Cys Tyr Glu Thr Tyr Pro Glu Ser Cys Leu taacgtgaat catccagagc tttgtggctg aagacactga tgctccagga ccctctgaac cacgacgt

TABLE 25 DNA Sequence (SEQ ID NO: 106) and  Protein Sequence (SEQ ID NO: 107) of Bt1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtg gtt tcc ttc act tca ggt cgt gca ttt cgt Thr Val Val Ser Phe Thr Ser Gly Arg Ala Phe Arg ggc agg aat cgc gca gcc gac gac aaa agg tct gac Gly Arg Asn Arg Ala Ala Asp Asp Lys Arg Ser Asp ctg gcc gct ctg agc gtc agg gga gga tgc tgt tcc Leu Ala Ala Leu Ser Val Arg Gly Gly Cys Cys Ser cat cct gcc tgt gcg gtg aat cat cca gag ctt tgt His Pro Ala Cys Ala Val Asn His Pro Glu Leu Cys ggc tgaagacgct gatgccccag gaccctctga accacgacgt Gly

TABLE 26 DNA Sequence (SEQ ID NO: 108) and  Protein Sequence (SEQ ID NO: 109) of Bt1.3 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc act tca ggt cgt gca tct ggt Thr Val Val Ser Phe Thr Ser Gly Arg Ala Ser Gly ggc agg aat gct gca gcc aaa gcg tct aac cgg atc Gly Arg Asn Ala Ala Ala Lys Ala Ser Asn Arg Ile gct atg gcc atc agc agt gga gca tgc tgt gca tat Ala Met Ala Ile Ser Ser Gly Ala Cys Cys Ala Tyr cct ccc tgt ttc gag gct tat cca gaa aga tgt ctg Pro Pro Cys Phe Glu Ala Tyr Pro Glu Arg Cys Leu taacgtgaat catccagacc tttgtggctg aagacgctga tgccccagga ccctctgaac cacgacgt

TABLE 27 DNA Sequence (SEQ ID NO: 110) and  Protein Sequence (SEQ ID NO: 111) of Bt1.4 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc act tca gat cgt gca ttt cgt Thr Val Val Ser Phe Thr Ser Asp Arg Ala Phe Arg ggc agg aat tcc gca gcc aac gac aaa agg tct gac Gly Arg Asn Ser Ala Ala Asn Asp Lys Arg Ser Asp ctg gcc gct ctg agc gtc agg aga gga tgc tgc tcc Leu Ala Ala Leu Ser Val Arg Arg Gly Cys Cys Ser cat ccc gcc tgt agc gtg aat cat cca gag ctt tgt His Pro Ala Cys Ser Val Asn His Pro Glu Leu Cys ggt aga aga cgc tgatgcccca ggaccctctg aaccacgacg Gly Arg Arg Arg t

TABLE 28 DNA Sequence (SEQ ID NO: 112) and  Protein Sequence (SEQ ID NO: 113) of Bt1.5 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc act tca ggt cgt gca tct ggt Thr Val Val Ser Phe Thr Ser Gly Arg Ala Ser Gly ggc agg aat gct gca gcc aaa gcg tct aac cgg atc Gly Arg Asn Ala Ala Ala Lys Ala Ser Asn Arg Ile gct ctg atc gtc agg aat gca gaa tgc tgt tat tat Ala Leu Ile Val Arg Asn Ala Glu Cys Cys Tyr Tyr cct ccc tgt tac gag gct tat cca gaa att tgt ctg Pro Pro Cys Tyr Glu Ala Tyr Pro Glu Ile Cys Leu taacgtgaat catccagacc tttgtggctg aagaccctga tgctccagga ccctctgaac cacgacgt

TABLE 29 DNA Sequence (SEQ ID NO: 114) and  Protein Sequence (SEQ ID NO: 115) of Pn1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc att tcc ttc act tca gat cgt gca tct gat Thr Val Ile Ser Phe Thr Ser Asp Arg Ala Ser Asp ggc ggg aat gcc gca gcg tct gac ctg atc gct ctg Gly Gly Asn Ala Ala Ala Ser Asp Leu Ile Ala Leu acc atc aag gga tgc tgt tct cat cct ccc tgt gcc Thr Ile Lys Gly Cys Cys Ser His Pro Pro Cys Ala atg aat aat cca gac tat tgt ggt tgacgacgct Met Asn Asn Pro Asp Tyr Cys Gly gatgctccag gaccctctga accacgacg

TABLE 30 DNA Sequence (SEQ ID NO: 116) and  Protein Sequence (SEQ ID NO: 117) of Pn1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc act tca gat cgt gca tct gat Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp ggc ggg aat gcc gca atg tct gac ctg atc gct ctg Gly Gly Asn Ala Ala Met Ser Asp Leu Ile Ala Leu acc atc aag gga tgc tgt tct cat cct ccc tgt ttc Thr Ile Lys Gly Cys Cys Ser His Pro Pro Cys Phe ctg aat aat cca gac tat tgt ggt tgacgacgct Leu Asn Asn Pro Asp Tyr Cys Gly gatgctccag gaccctctga accacgacg

TABLE 31 DNA Sequence (SEQ ID NO: 118) and  Protein Sequence (SEQ ID NO: 119) of Sm1.3 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc cct tca gat cgt gaa tct gat Thr Val Val Ser Phe Pro Ser Asp Arg Glu Ser Asp ggc gcg aat gac gaa gcc cgc acc gac gag cct gag Gly Ala Asn Asp Glu Ala Arg Thr Asp Glu Pro Glu gag cac gga ccg gac agg aat gga tgc tgt agg aat Glu His Gly Pro Asp Arg Asn Gly Cys Cys Arg Asn cct gcc tgt gag agc cac aga tgt ggt tgacgacgct Pro Ala Cys Glu Ser His Arg Cys Gly gatgctccag gaccctctga accacgacg

TABLE 32 DNA Sequence (SEQ ID NO: 120) and  Protein Sequence (SEQ ID NO: 121) of Cr1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc cct tca gat cgt gca tct gat Thr Val Val Ser Phe Pro Ser Asp Arg Ala Ser Asp ggc agg aat gcc gca gcc agc gac aga gcg tct gac Gly Arg Asn Ala Ala Ala Ser Asp Arg Ala Ser Asp gcg gcc cac cag gga tgc tgt tcc aac cct gtc tgt Ala Ala His Gln Gly Cys Cys Ser Asn Pro Val Cys cac gtg gaa cat cca gaa ctt tgt cgt aga aga cgc His Val Glu His Pro Glu Leu Cys Arg Arg Arg Arg tgatgctcca ggaccctctg aaccacgacg

TABLE 33 DNA Sequence (SEQ ID NO: 122) and  Protein Sequence (SEQ ID NO: 123) of Cr1.3 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc ttc cct tca aat cgt gaa tct gat Thr Val Val Ser Phe Pro Ser Asn Arg Glu Ser Asp ggc gcg aat gcc gaa gtc cgc acc gac gag cct gag Gly Ala Asn Ala Glu Val Arg Thr Asp Glu Pro Glu gag cac gac gaa ctg ggc ggg aat gga tgc tgt ggg Glu His Asp Glu Leu Gly Gly Asn Gly Cys Cys Gly aat cct gac tgt acg agc cac agt tgt gat Asn Pro Asp Cys Thr Ser His Ser Cys Asp tgacgacgct gatgctccag gaccctctga accacgacg

TABLE 34 DNA Sequence (SEQ ID NO: 124) and Protein Sequence (SEQ ID NO: 125) of EpI atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc acc gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser ttc act tca gat cgt gca tct gat agc agg aag gac gca gcg tct ggc Phe Thr Ser Asp Arg Ala Ser Asp Ser Arg Lys Asp Ala Ala Ser Gly ctg atc gct ctg acc atc aag gga tgc tgt tct gat cct cgc tgt aac Leu Ile Ala Leu Thr Ile Lys Gly Cys Cys Ser Asp Pro Arg Cys Asn atg aat aat cca gac tat tgt ggt tgacgacgct gatgctccag gaccctctga Met Asn Asn Pro Asp Tyr Cys Gly accacgacg

TABLE 35 DNA Sequence (SEQ ID NO: 126) and Protein Sequence (SEQ ID NO: 127) of Sn1.1 atg tcc acc gtg ttt ctg ttg gtt gtc ctc gca acc acc gtc gtt tcc Met Ser Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser ttc act gta gat cgt gca tct gat ggc agg gat gtc gca atc gac gac Phe Thr Val Asp Arg Ala Ser Asp Gly Arg Asp Val Ala Ile Asp Asp aga ttg gtg tct ctc cct cag atc gcc cat gct gac tgt tgt tcc gat Arg Leu Val Ser Leu Pro Gln Ile Ala His Ala Asp Cys Cys Ser Asp cct gcc tgc aag cag acg ccc ggt tgt cgt taaagacgct gctgctccag Pro Ala Cys Lys Gln Thr Pro Gly Cys Arg gaccctctga accacgacg

TABLE 36 DNA Sequence (SEQ ID NO: 128) and Protein Sequence (SEQ ID NO: 129) of Sn1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc acc gtc gct tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Ala Ser ttc att atc gat gat cca tct gat ggc agg aat att gca gtc gac gac Phe Ile Ile Asp Asp Pro Ser Asp Gly Arg Asn Ile Ala Val Asp Asp aga ggg ctt ttc tct acg ctc ttc cat gct gat tgc tgt gaa aat cct Arg Gly Leu Phe Ser Thr Leu Phe His Ala Asp Cys Cys Glu Asn Pro gcc tgt aga cac acg cag ggt tgt tgatctttgt tcttcaaaga cactgctggc Ala Cys Arg His Thr Gln Gly Cys ccaggaccct ctgaaccacg acg

TABLE 37 DNA Sequence (SEQ ID NO: 130) and Protein Sequence (SEQ ID NO: 131) of Da1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc acc gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser ttc act tca gat cgt gca ttt cgt ggc agg aat gcc gca gcc aaa gag Phe Thr Ser Asp Arg Ala Phe Arg Gly Arg Asn Ala Ala Ala Lys Glu tct ggc ctg gtc ggt ctg acc gac aag acg cga gga tgc tgt tct cat Ser Gly Leu Val Gly Leu Thr Asp Lys Thr Arg Gly Cys Cys Ser His cct gcc tgt aac gta gat cat cca gaa att tgt ggt tgaagacgct Pro Ala Cys Asn Val Asp His Pro Glu Ile Cys Gly gatgctccag gaccctctga accacgacgt

TABLE 38 DNA Sequence (SEQ ID NO: 132) and Protein Sequence (SEQ ID NO: 133) of Da1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc acc gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser ttc act tca gat ggt gca tct gat gac agg aaa gcc gct gcg tct gac Phe Thr Ser Asp Gly Ala Ser Asp Asp Arg Lys Ala Ala Ala Ser Asp ctg atc act ctg acc atc aag gga tgc tgt tct cgt cct ccc tgt atc Leu Ile Thr Leu Thr Ile Lys Gly Cys Cys Ser Arg Pro Pro Cys Ile gcg aat aat cca gac ttg tgt ggt cga cga cgc tgatgctcca ggaccctctg Ala Asn Asn Pro Asp Leu Cys Gly Arg Arg Arg

TABLE 39 DNA Sequence (SEQ ID NO: 134) and Protein Sequence (SEQ ID NO: 135) of Da1.3 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc act gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser tcc act tca ggt cgt cgt gca ttt cat ggc agg aat gcc gca gcc aaa Ser Thr Ser Gly Arg Arg Ala Phe His Gly Arg Asn Ala Ala Ala Lys gcg tct gga ctg gtc ggt ctg act gac agg aga cca caa tgc tgt agt Ala Ser Gly Leu Val Gly Leu Thr Asp Arg Arg Pro Gln Cys Cys Ser gat cct cgc tgt aac gta ggt cat cca gaa ctt tgt ggt gga aga cgc Asp Pro Arg Cys Asn Val Gly His Pro Glu Leu Cys Gly Gly Arg Arg tgatgctcca ggaccctctg aaccacaacg t

TABLE 40 DNA Sequence (SEQ ID NO: 136) and  Protein Sequence (SEQ ID NO: 137) of Da1.4 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc act gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser tcc act tca ggt cgt gca ttt cat ggc agg aat gcc gca gcc aaa gcg Ser Thr Ser Gly Arg Ala Phe His Gly Arg Asn Ala Ala Ala Lys Ala tct ggc ctg gtc ggt ctg acc gac aag agg caa gta tgc tgt agt gat Ser Gly Leu Val Gly Leu Thr Asp Lys Arg Gln Val Cys Cys Ser Asp cct cgc tgt aac gta ggt cat cca gaa att tgt ggt gga aga cgc Pro Arg Cys Asn Val Gly His Pro Glu Ile Cys Gly Gly Arg Arg tgatgctcca ggaccctctg aaccacgacg t

TABLE 41 DNA Sequence (SEQ ID NO: 138) and Protein Sequence (SEQ ID NO: 139)of A1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg aca acc act gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Thr Thr Thr Val Val Ser ttc cct tca gat agt gca tct ggt ggc agg gat gac gag gcc aaa gac Phe Pro Ser Asp Ser Ala Ser Gly Gly Arg Asp Asp Glu Ala Lys Asp gaa agg tct gac atg tac gaa ttg aaa cgg aat gga cgc tgt tgc cat Glu Arg Ser Asp Met Tyr Glu Leu Lys Arg Asn Gly Arg Cys Cys His cct gcc tgt ggt ggc aaa tac gtt aaa tgt gga cgc tgatgctcca Pro Ala Cys Gly Gly Lys Tyr Val Lys Cys Gly Arg ggaccctctc gaaccacg

TABLE 42 DNA Sequence (SEQ ID NO: 140) and Protein Sequence (SEQ ID NO: 141) of Bu1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc act gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser ttc tct aca gat gat gaa tct gat ggc tcg aat gaa gaa ccc agc gcc Phe Ser Thr Asp Asp Glu Ser Asp Gly Ser Asn Glu Glu Pro Ser Ala gac cag act gcc agg tcc tca atg aac agg gcg cct gga tgc tgt aac Asp Gln Thr Ala Arg Ser Ser Met Asn Arg Ala Pro Gly Cys Cys Asn aat cct gcc tgt gtg aag cac aga tgt gga tgacgctgat gctccaggac Asn Pro Ala Cys Val Lys His Arg Cys Gly cctctgaacc acgacgt

TABLE 43 DNA Sequence (SEQ ID NO: 142) and Protein Sequence (SEQ ID NO: 143) of Bu1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc act gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser ttc tct aca gat gat gaa tct gat ggc tcg aat gaa gaa ccc agc gcc Phe Ser Thr Asp Asp Glu Ser Asp Gly Ser Asn Glu Glu Pro Ser Ala gac cag gct gcc agg tcc gca atg aac agg ccg cct gga tgc tgt aac Asp Gln Ala Ala Arg Ser Ala Met Asn Arg Pro Pro Gly Cys Cys Asn aat cct gcc tgt gtg aag cac aga tgt ggt gga tgacgctgat gctccaggac Asn Pro Ala Cys Val Lys His Arg Cys Gly Gly cctctgaacc acgacgt

TABLE 44 DNA Sequence (SEQ ID NO: 144) and Protein Sequence (SEQ ID NO: 145) of Bu1.3 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc act gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser ttc cct tca gat cgt gac tct gat ggc gcg gat gcc gaa gcc agt gac Phe Pro Ser Asp Arg Asp Ser Asp Gly Ala Asp Ala Glu Ala Ser Asp gag cct gtt gag ttc gaa agg gac gag aat gga tgc tgt tgg aat cct Glu Pro Val Glu Phe Glu Arg Asp Glu Asn Gly Cys Cys Trp Asn Pro tcc tgt ccg agg ccc aga tgt aca gga cga cgc taatgctcca ggaccctctg Ser Cys Pro Arg Pro Arg Cys Thr Gly Arg Arg aaccacgacg t

TABLE 45 DNA Sequence (SEQ ID NO: 146) and Protein Sequence (SEQ ID NO: 170) of Bu1.4 atg ttc acc gtg ttt ctg ttg gtt gtc ttg aca acc act gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Thr Thr Thr Val Val Ser ttc cct tca gat cgt gca tct gat ggc agg aat gcc gca gcc aac gac Phe Pro Ser Asp Arg Ala Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp aaa gcg tct gac gtg gtc acg ctg gtc ctc aag gga tgc tgt tcc acc Lys Ala Ser Asp Val Val Thr Leu Val Leu Lys Gly Cys Cys Ser Thr cct ccc tgt gct gtg ctg tat tgt ggt aga aga cgc tgatgctcca Pro Pro Cys Ala Val Leu Tyr Cys Gly Arg Arg Arg ggaccctctg aaccacgacg t

TABLE 46 DNA Sequence (SEQ ID NO: 148) and Protein Sequence (SEQ ID NO: 149) of Di1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttc gca tcc tct gtc acc tta Met Phe Thr Val Phe Leu Leu Val Val Phe Ala Ser Ser Val Thr Leu gat cgt gca tct tat ggc agg tat gcc tca ccc gtc gac aga gcg tct Asp Arg Ala Ser Tyr Gly Arg Tyr Ala Ser Pro Val Asp Arg Ala Ser gcc ctg atc gct cag gcc atc ctt cga gat tgc tgc tcc aat cct cct Ala Leu Ile Ala Gln Ala Ile Leu Arg Asp Cys Cys Ser Asn Pro Pro tgt gcc cat aat aat cca gac tgt cgt taaagacgct gcttgctcca Cys Ala His Asn Asn Pro Asp Cys Arg ggaccctct gaaccacgacg t

TABLE 47 DNA Sequence (SEQ ID NO: 150) and Protein Sequence (SEQ ID NO: 151) of T1 gga tgc tgt tct aat cct ccc tgt atc gcg aag aat cca cac atg tgt Gly Cys Cys Ser Asn Pro Pro Cys Ile Ala Lys Asn Pro His Met Cys ggt gga aga cgc tga Gly Gly Arg Arg

TABLE 48 DNA Sequence (SEQ ID NO: 152) and Protein Sequence (SEQ ID NO: 153) of Cn1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc act gtc gtt tcc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr Thr Val Val Ser ttc cct tca gat cgt gca tct gat ggc agg aat gcc gca gcc aac gac Phe Pro Ser Asp Arg Ala Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp aaa gcg tct gac gtg atc acg ctg gcc ctc aag gga tgc tgt tcc aac Lys Ala Ser Asp Val Ile Thr Leu Ala Leu Lys Gly Cys Cys Ser Asn cct gtc tgt cac ttg gag cat tca aac ctt tgt ggt aga aga cgc Pro Val Cys His Leu Glu His Ser Asn Leu Cys Gly Arg Arg Arg tgatgctcca ggaccctctg aaccacgacg t

TABLE 49 DNA Sequence (SEQ ID NO: 233) and Protein Sequence (SEQ ID NO: 234) of Im1.1 tct gat gga aag agt gcc gcg gcc aaa gcc aaa ccg Ser Asp Gly Lys Ser Ala Ala Ala Lys Ala Lys Pro tct cac ctg acg gct cca ttc atc agg gac gaa tgc Ser His Leu Thr Ala Pro Phe Ile Arg Asp Glu Cys tgt tcc gat tct cgc tgt ggc aag aac tgt ctt tga Cys Ser Asp Ser Arg Cys Gly Lys Asn Cys Leu

TABLE 50 DNA Sequence (SEQ ID NO: 235) and Protein Sequence (SEQ ID NO: 236) of Im1.2 ttt gat gga agg aat gcc cca gcc gac gac aaa gcg Phe Asp Gly Arg Asn Ala Pro Ala Asp Asp Lys Ala tct gac ctg atc gct caa atc gtc agg aga gca tgc Ser Asp Leu Ile Ala Gln Ile Val Arg Arg Ala Cys tgt tcc gat cgt cgc tgt aga tgg agg tgt ggt tga Cys Ser Asp Arg Arg Cys Arg Trp Arg Cys Gly

TABLE 51 DNA Sequence (SEQ ID NO: 237) and Protein Sequence (SEQ ID NO: 238) of Rg1.2 tct gat gga agg aat gcc gca gcc gac gcc aga gcg Ser Asp Gly Arg Asn Ala Ala Ala Asp Ala Arg Ala tct ccc cgg atc gct ctt ttc ctc agg ttc aca tgc Ser Pro Arg Ile Ala Leu Phe Leu Arg Phe Thr Cys tgt agg aga ggt acc tgt tcc cag cac tgt ggt Cys Arg Arg Gly Thr Cys Ser Gln His Cys Gly tgaagacact gctgctccag gaccctctga accacgacgt

TABLE 52 DNA Sequence (SEQ ID NO: 239) and Protein Sequence (SEQ ID NO: 240) of Rg1.6 tct aat gga agg aat gcc gca gcc gac gcc aaa gcg Ser Asn Gly Arg Asn Ala Ala Ala Asp Ala Lys Ala tct caa cgg atc gct cca ttc ctc agg gac tat tgc Ser Gln Arg Ile Ala Pro Phe Leu Arg Asp Tyr Cys tgt agg aga cat gcc tgt acg ttg att tgt ggt Cys Arg Arg His Ala Cys Thr Leu Ile Cys Gly tgaagacgct gctgctccag gaccctctga accacgacgt

TABLE 53 DNA Sequence (SEQ ID NO: 241) and Protein Sequence (SEQ ID NO: 242) of Rg1.6A tct aat gga agg aat gcc gca gcc gac gcc aaa gcg Ser Asn Gly Arg Asn Ala Ala Ala Asp Ala Lys Ala tct caa cgg atc gct cca ttc ctc agg gac tat tgc Ser Gln Arg Ile Ala Pro Phe Leu Arg Asp Tyr Cys tgt agg aga cct ccc tgt acg ttg att tgt ggt Cys Arg Arg Pro Pro Cys Thr Leu Ile Cys Gly tgaagacgct gctgctccag gaccctctga accacgacgt

TABLE 54 DNA Sequence (SEQ ID NO: 243) and Protein Sequence (SEQ ID NO: 244) of Rg1.7 tct aat aaa agg aag aat gcc gca atg ctt gac atg Ser Asn Lys Arg Lys Asn Ala Ala Met Leu Asp Met atc gct caa cac gcc ata agg ggt tgc tgt tcc gat Ile Ala Gln His Ala Ile Arg Gly Cys Cys Ser Asp cct cgc tgt aga tat aga tgt cgt tgaagacgct Pro Arg Cys Arg Tyr Arg Cys Arg gctgctccag gaccctctga accacgacgt

TABLE 55 DNA Sequence (SEQ ID NO: 245) and Protein Sequence (SEQ ID NO: 246) of Rg1.9 ttt aat gga agg agt gcc gca gcc gac caa aat gcg Phe Asn Gly Arg Ser Ala Ala Ala Asp Gln Asn Ala cct ggc ctg atc gct caa gtc gtc aga gga ggg tgc Pro Gly Leu Ile Ala Gln Val Val Arg Gly Gly Cys tgt tcc gat ccc cgc tgc gcc tgg aga tgt ggt Cys Ser Asp Pro Arg Cys Ala Trp Arg Cys Gly tgaagacgtt gctgctccag gaccctctga accacgacgt

TABLE 56 DNA Sequence (SEQ ID NO: 247) and Protein Sequence (SEQ ID NO: 248) of Rg1.10 ttt gat gga agg aat gcc gca gcc gac gcc aaa gtg Phe Asp Gly Arg Asn Ala Ala Ala Asp Ala Lys Val att aac acg gtc gct cga atc gcc tgg gat ata tgc Ile Asn Thr Val Ala Arg Ile Ala Trp Asp Ile Cys tgt tcc gaa cct gac tgt aac cat aaa tgt gtt Cys Ser Glu Pro Asp Cys Asn His Lys Cys Val tgaagacgct tctgctccag gaccctctga accacgacgt

TABLE 57 DNA Sequence (SEQ ID NO: 249) and Protein Sequence (SEQ ID NO: 250) of Rg1.11 tct aat aaa agg aag aat gcc gca atg ctt gac atg Ser Asn Lys Arg Lys Asn Ala Ala Met Leu Asp Met atc gct caa cac gcc ata agg ggt tgc tgt tcc gat Ile Ala Gln His Ala Ile Arg Gly Cys Cys Ser Asp cct cgc tgt aaa cat cag tgt ggt tgaagacgct Pro Arg Cys Lys His Gln Cys Gly gctgctccag gaccctctga accacgacgt

TABLE 58 DNA Sequence (SEQ ID NO: 251) and Protein Sequence (SEQ ID NO: 252) of Ms1.7 atc aag aat aca gca gcc agc aac aaa gcg tct agc Ile Lys Asn Thr Ala Ala Ser Asn Lys Ala Ser Ser ctg gtg gct ctt gtt gtc agg gga tgc tgt tac aat Leu Val Ala Leu Val Val Arg Gly Cys Cys Tyr Asn cct gtc tgc aag aaa tat tat tgt tgg aaa ggc Pro Val Cys Lys Lys Tyr Tyr Cys Trp Lys Gly tgatgctcca ggaccctctg aaccacgacg t

TABLE 59 DNA Sequence (SEQ ID NO: 253) and Protein Sequence (SEQ ID NO: 254) of P1.7 tct gaa ggc agg aat gct gaa gcc atc gac aac gcc Ser Glu Gly Arg Asn Ala Glu Ala Ile Asp Asn Ala tta gac cag agg gat cca aag cga cag gag ccg ggg Leu Asp Gln Arg Asp Pro Lys Arg Gln Glu Pro Gly tgc tgt agg cat cct gcc tgt ggg aag aac aga tgt Cys Cys Arg His Pro Ala Cys Gly Lys Asn Arg Cys gga aga cgc tgatgctccag gaccctctg aaccacgacg t Gly Arg Arg

TABLE 60 DNA Sequence (SEQ ID NO: 255) and Protein Sequence (SEQ ID NO: 256) of Ms1.2 tct gat ggc agg aat att gca gtc gac gac aga tgg Ser Asp Gly Arg Asn Ile Ala Val Asp Asp Arg Trp tct ttc tat acg ctc ttc cat gct act tgc tgt gcc Ser Phe Tyr Thr Leu Phe His Ala Thr Cys Cys Ala gat cct gac tgt aga ttc cgg ccc ggt tgt  Asp Pro Asp Cys Arg Phe Arg Pro Gly Cys tgatctttgt tcttcaaaga cgctgctggc ccaggaccct ctgaaccacg acgt

TABLE 61 DNA Sequence (SEQ ID NO: 257) and Protein Sequence (SEQ ID NO: 258) of Ms1.3 atc aag aat act gca gcc agc aac aaa gcg cct agc Ile Lys Asn Thr Ala Ala Ser Asn Lys Ala Pro Ser ctg gtg gct att gcc gtc agg gga tgc tgt tac aat Leu Val Ala Ile Ala Val Arg Gly Cys Cys Tyr Asn cct tcc tgt tgg ccg aaa aca tat tgt agt Pro Ser Cys Trp Pro Lys Thr Tyr Cys Ser tggaaaggct gatgctccag gaccctctga accacgacgt

TABLE 62 DNA Sequence (SEQ ID NO: 259) and Protein Sequence (SEQ ID NO: 260) of Ms1.4 tct gat agc agg aat gtc gca atc gag gac aga gtg Ser Asp Ser Arg Asn Val Ala Ile Glu Asp Arg Val tct gac ctg cac tct atg ttc ttc gat gtt tct tgc Ser Asp Leu His Ser Met Phe Phe Asp Val Ser Cys tgt agc aat cct acc tgt aaa gaa acg tat ggt tgt Cys Ser Asn Pro Thr Cys Lys Glu Thr Tyr Gly Cys tgatcgttgg ttttgaagac gctgatgctc caggaccctc

TABLE 63 DNA Sequence (SEQ ID NO: 261) and Protein Sequence (SEQ ID NO: 262) of Ms1.5 tct gtt ggc agg aat att gca gtc gac gac aga ggg Ser Val Gly Arg Asn Ile Ala Val Asp Asp Arg Gly att ttc tct acg ctc ttc cat gct cat tgc tgt gcc Ile Phe Ser Thr Leu Phe His Ala His Cys Cys Ala aat ccc atc tgt aaa aac acg ccc ggt tgt Asn Pro Ile Cys Lys Asn Thr Pro Gly Cys tgatctttgt tcttcaaaga cgctgctggc ccaggaccct  ctgaaccacg acgt

TABLE 64 DNA Sequence (SEQ ID NO: 263) and Protein Sequence (SEQ ID NO: 264) of Ms1.8 tcc gat ggc agg aat gtc gca atc gac gac aga gtg Ser Asp Gly Arg Asn Val Ala Ile Asp Asp Arg Val tct gac ctg cac tct atg ttc ttc gat att gct tgc Ser Asp Leu His Ser Met Phe Phe Asp Ile Ala Cys tgt aac aat cct acc tgt aaa gaa acg tat ggt tgt Cys Asn Asn Pro Thr Cys Lys Glu Thr Tyr Gly Cys tgatcgttgg ttttgaagac gctgatgctc caggaccctc tgaaccacga cgt

TABLE 65 DNA Sequence (SEQ ID NO: 265) and Protein Sequence (SEQ ID NO: 266) of Ms1.9 tct gat ggc agg aat gtc gca atc gag gac aga gtg Ser Asp Gly Arg Asn Val Ala Ile Glu Asp Arg Val tct gac ctg ctc tct atg ctc ttc gat gtt gct tgc Ser Asp Leu Leu Ser Met Leu Phe Asp Val Ala Cys tgt agc aat cct gtc tgt aaa gaa acg tat ggt tgt Cys Ser Asn Pro Val Cys Lys Glu Thr Tyr Gly Cys tgatcgttgg ttttgaagac gctgatgctc caggaccctc tgaaccacga cgt

TABLE 66 DNA Sequence (SEQ ID NO: 267) and Protein Sequence (SEQ ID NO: 268) of Bt1.7 tat gat ggc agg aat gct gcc gcc gac gac aaa gct Tyr Asp Gly Arg Asn Ala Ala Ala Asp Asp Lys Ala ttt gac ctg ctg gct atg acc ata agg gga gga tgc Phe Asp Leu Leu Ala Met Thr Ile Arg Gly Gly Cys tgt tcc tat cct ccc tgt atc gcg agt aat cct aaa Cys Ser Tyr Pro Pro Cys Ile Ala Ser Asn Pro Lys tgt ggt gga aga cgc tgatgctcca ggaccctctg Cys Gly Gly Arg Arg aaccacaacg t

TABLE 67 DNA Sequence (SEQ ID NO: 269) and Protein Sequence (SEQ ID NO: 270) of Lv1.5 ttt gat ggc agg aat gct gca ggc aac gcc aaa atg Phe Asp Gly Arg Asn Ala Ala Gly Asn Ala Lys Met tcc gcc ctg atg gcc ctg acc atc agg gga tgc tgt Ser Ala Leu Met Ala Leu Thr Ile Arg Gly Cys Cys tcc cat cct gtc tgt agc gcg atg agt cca atc tgt Ser His Pro Val Cys Ser Ala Met Ser Pro Ile Cys ggc tgaagacgct gatgccccag gaccctctga accacgacgt Gly

TABLE 68 DNA Sequence (SEQ ID NO: 271) and Protein Sequence (SEQ ID NO: 272) of Ms1.10 atc aag aat gct gca gct gac gac aaa gca tct gac Ile Lys Asn Ala Ala Ala Asp Asp Lys Ala Ser Asp ctg ctc tct cag atc gtc agg aat gct gca tcc aat Leu Leu Ser Gln Ile Val Arg Asn Ala Ala Ser Asn gac aaa ggg tct gac ctg atg act ctt gcc ctc agg Asp Lys Gly Ser Asp Leu Met Thr Leu Ala Leu Arg gga tgc tgt aaa aat cct tac tgt ggt gcg tcg aaa Gly Cys Cys Lys Asn Pro Tyr Cys Gly Ala Ser Lys aca tat tgt ggt aga aga cgc tgatgctcca ggaccctctg Thr Tyr Cys Gly Arg Arg Arg aaccacgacg t

TABLE 69 DNA Sequence (SEQ ID NO: 273) and Protein Sequence (SEQ ID NO: 274) of Om1.1 tctgatggca ggaatgccgc agcgtctgac ctgatggat ctg                                             Leu acc atc aag gga tgc tgt tct tat cct ccc tgt ttc Thr Ile Lys Gly Cys Cys Ser Tyr Pro Pro Cys Phe gcg act aat cca gac tgt ggt cga cga cgc Ala Thr Asn Pro Asp Cys Gly Arg Arg Arg tgatgctcca ggaccctctg aaccacgacg t

TABLE 70 DNA Sequence (SEQ ID NO: 275) and Protein Sequence (SEQ ID NO: 276) of R1.6 ttt gat ggc agg aat gcc gca gcc gac tac aaa ggg Phe Asp Gly Arg Asn Ala Ala Ala Asp Tyr Lys Gly tct gaa ttg ctc gct atg acc gtc agg gga gga tgc Ser Glu Leu Leu Ala Met Thr Val Arg Gly Gly Cys tgt tcc tat cct ccc tgt atc gca aat aat cct ctt Cys Ser Tyr Pro Pro Cys Ile Ala Asn Asn Pro Leu tgt gct gga aga cgc tga Cys Ala Gly Arg Arg

TABLE 71 DNA Sequence (SEQ ID NO: 277) and Protein Sequence (SEQ ID NO: 278) of R1.7 ttt gat ggc agg aat gcc gca gcc gac tac aaa ggg Phe Asp Gly Arg Asn Ala Ala Ala Asp Tyr Lys Gly tct gaa ttg ctc gct atg acc gtc agg gga gga tgc Ser Glu Leu Leu Ala Met Thr Val Arg Gly Gly Cys tgt tcc tat cct ccc tgt atc gca aat aat cct ttt Cys Ser Tyr Pro Pro Cys Ile Ala Asn Asn Pro Phe tgt gct gga aga cgc tga Cys Ala Gly Arg Arg

TABLE 72 DNA Sequence (SEQ ID NO: 279) and Protein Sequence (SEQ ID NO: 280) of Vr1.1 tct tat gac agg tat gcc tcg ccc gtc gac aga gcg Ser Tyr Asp Arg Tyr Ala Ser Pro Val Asp Arg Ala tct gcc ctg atc gct cag gcc atc ctt cga gat tgc Ser Ala Leu Ile Ala Gln Ala Ile Leu Arg Asp Cys tgt tcc aat cct ccc tgt tcc caa aat aat cca gac Cys Ser Asn Pro Pro Cys Ser Gln Asn Asn Pro Asp tgt atg taaagacgct gcttgctcca ggaccctctg Cys Met aaccacgacg t

TABLE 73 DNA Sequence (SEQ ID NO: 281) and Protein Sequence (SEQ ID NO: 282) of Vr1.2 tct tat ggc agg tat gcc tca ccc gtc gac aga gcg Ser Tyr Gly Arg Tyr Ala Ser Pro Val Asp Arg Ala tct gcc ctg atc gct cag gcc atc ctt cga gat tgc Ser Ala Leu Ile Ala Gln Ala Ile Leu Arg Asp Cys tgc tcc aat cct cct tgt gcc cat aat aat cca gac Cys Ser Asn Pro Pro Cys Ala His Asn Asn Pro Asp tgt cgt taaagacgct gcttgctcca ggaccctctg Cys Arg aaccacgacg t

TABLE 74 DNA Sequence (SEQ ID NO: 283) and Protein Sequence (SEQ ID NO: 284) of A1.4 tct gat ggc agg aat gcc gca gcc aac gac aaa gcg Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala tct ggc atg agc gcg ctg gcc gtc aat gaa tgc tgt Ser Gly Met Ser Ala Leu Ala Val Asn Glu Cys Cys acc aac cct gtc tgt cac gcg gaa cat caa gaa ctt Thr Asn Pro Val Cys His Ala Glu His Gln Glu Leu tgt gct aga aga cgc tga Cys Ala Arg Arg Arg

TABLE 75 DNA Sequence (SEQ ID NO: 285) and Protein Sequence (SEQ ID NO: 286) of A1.5 tct gat ggc agg aat gcc gca gcc aac gac aaa gcg Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala tct gac gtg atc acg ctg gcc ctc aag gga tgc tgt Ser Asp Val Ile Thr Leu Ala Leu Lys Gly Cys Cys tcc aac cct gtc tgt cac ttg gag cat tca aac ctt Ser Asn Pro Val Cys His Leu Glu His Ser Asn Leu tgt ggt aga aga cgc tga Cys Gly Arg Arg Arg

TABLE 76 DNA Sequence (SEQ ID NO: 287) and Protein Sequence (SEQ ID NO: 288) of A1.6 tct gat ggc agg aat gcc gca gcc aac gac aaa gcg Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala tct ggc atg agc gcg ctg gcc gtc aat gaa tgc tgt Ser Gly Met Ser Ala Leu Ala Val Asn Glu Cys Cys acc aac cct gtc tgt cac gtg gaa cat caa gaa ctt Thr Asn Pro Val Cys His Val Glu His Gln Glu Leu tgt gct aga aga cgc tga Cys Ala Arg Arg Arg

TABLE 77 DNA Sequence (SEQ ID NO: 289) and Protein Sequence (SEQ ID NO: 290) of Af1.1 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc act tca gat cgt gca ttt cgt Thr Val Val Ser Phe Thr Ser Asp Arg Ala Phe Arg ggc agg aat gcc gca gcc aaa gcg tct ggc ctg gtc Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu Val ggt ctg acc gac aag agg caa gaa tgc tgt tct tat Gly Leu Thr Asp Lys Arg Gln Glu Cys Cys Ser Tyr cct gcc tgt aac cta gat cat cca gaa ctt tgt ggt  Pro Ala Cys Asn Leu Asp His Pro Glu Leu Cys Gly tgaagacgct gatgctccag gaccctctga accacgacgt

TABLE 78 DNA Sequence (SEQ ID NO: 291) and Protein Sequence (SEQ ID NO: 292) of Af1.2 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr act gtc gtt tcc tcc act tca ggt cgt cgt gca ttt Thr Val Val Ser Ser Thr Ser Gly Arg Arg Ala Phe cgt ggc agg aat gcc gca gcc aaa gcg tct gga ctg Arg Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu gtc ggt ctg act gac agg aga cca gaa tgc tgt agt Val Gly Leu Thr Asp Arg Arg Pro Glu Cys Cys Ser gat cct cgc tgt aac tcg act cat cca gaa ctt tgt Asp Pro Arg Cys Asn Ser Thr His Pro Glu Leu Cys ggt gga aga cgc tgatgctcca ggaccctctg aaccacgacg Gly Gly Arg Arg t

TABLE 79 DNA Sequence (SEQ ID NO: 293) and Protein Sequence (SEQ ID NO: 294) of Ar1.2 tct gat ggc agg aat gcc gca gcc aac gcg ttt gac Ser Asp Gly Arg Asn Ala Ala Ala Asn Ala Phe Asp ctg atc gat ctg acc gcc agg cta aat tgc tgt atg Leu Ile Asp Leu Thr Ala Arg Leu Asn Cys Cys Met att ccc ccc tgt tgg aag aaa tat gga gac aga tgt Ile Pro Pro Cys Trp Lys Lys Tyr Gly Asp Arg Cys agt gaa gta cgc tgatgctcca ggaccctctg aaccacgacg Ser Glu Val Arg t

TABLE 80 DNA Sequence (SEQ ID NO: 295) and Protein Sequence (SEQ ID NO: 296) of Ar1.3 tct gat ggc agg aat gcc gca cgc aaa gcg ttt ggc Ser Asp Gly Arg Asn Ala Ala Arg Lys Ala Phe Gly tgc tgc gac tta ata ccc tgt ttg gag aga tat ggt Cys Cys Asp Leu Ile Pro Cys Leu Glu Arg Tyr Gly aac aga tgt aat gaa gtg cac tgatgctcca ggaccctctg Asn Arg Cys Asn Glu Val His  aaccacgcga cgt

TABLE 81 DNA Sequence (SEQ ID NO: 297) and Protein Sequence (SEQ ID NO: 298) of Ar1.4 tct gat ggc agc aat gcc gca gcc aac gag ttt gac Ser Asp Gly Ser Asn Ala Ala Ala Asn Glu Phe Asp ctg atc gct ctg acc gcc agg cta ggt tgc tgt aac Leu Ile Ala Leu Thr Ala Arg Leu Gly Cys Cys Asn gtt aca ccc tgt tgg gag aaa tat gga gac aaa tgt Val Thr Pro Cys Trp Glu Lys Tyr Gly Asp Lys Cys aat gaa gta cgc tgatgcttca ggaccctctg aaccacgacg Asn Glu Val Arg T

TABLE 82 DNA Sequence (SEQ ID NO: 299) and Protein Sequence (SEQ ID NO: 300) of Ar1.5 tct gat ggc agg aat gtc gca gca aaa gcg ttt cac Ser Asp Gly Arg Asn Val Ala Ala Lys Ala Phe His cgg atc ggc cgg acc atc agg gat gaa tgc tgt tcc Arg Ile Gly Arg Thr Ile Arg Asp Glu Cys Cys Ser aat cct gcc tgt agg gtg aat aat cca cac gtt tgt Asn Pro Ala Cys Arg Val Asn Asn Pro His Val Cys aga cga cgc tgatgctcca ggaccctctg aaccacgacg t Arg Arg Arg

TABLE 83 DNA Sequence (SEQ ID NO: 301) and Protein Sequence (SEQ ID NO: 302) of Ar1.6 tct gat ggc agg aat gcc gca gcc aac gcg ttt gac Ser Asp Gly Arg Asn Ala Ala Ala Asn Ala Phe Asp ctg atg cct ctg acc gcc agg cta aat tgc tgt agc Leu Met Pro Leu Thr Ala Arg Leu Asn Cys Cys Ser att ccc ggc tgt tgg aac gaa tat aaa gac aga tgt Ile Pro Gly Cys Trp Asn Glu Tyr Lys Asp Arg Cys agt aaa gta cgc tgatgctcca ggaccctctg aaccacgacgt Ser Lys Val Arg

TABLE 84 DNA Sequence (SEQ ID NO: 303) and Protein Sequence (SEQ ID NO: 304) of Ay1.2 tctgatggca ggaatgccgc agccgacgac aaagcgtctg                                             acctggtcgc t ctg gtc gtc agg gga gga tgc tgt tcc              Leu Val Val Arg Gly Gly Cys Cys Ser cac cct gtc tgt tac ttt aat aat cca caa atg tgt His Pro Val Cys Tyr Phe Asn Asn Pro Gln Met Cys cgt gga aga cgc tgatgctcca ggaccctctg aaccacgacg Arg Gly Arg Arg t

TABLE 85 DNA Sequence (SEQ ID NO: 305) and Protein Sequence (SEQ ID NO: 306) of Ay1.3 tctgatggca ggaatgccgc agccgacgac aaagcgtctg                                             acctggtcgc t ctg gcc gtc agg gga gga tgc tgt tcc              Leu Ala Val Arg Gly Gly Cys Cys Ser cac cct gtc tgt aac ttg aat aat cca caa atg tgt His Pro Val Cys Asn Leu Asn Asn Pro Gln Met Cys cgt gga aga cgc tgatgctccaggaccctctg aaccacgacg t Arg Gly Arg Arg

TABLE 86 DNA Sequence (SEQ ID NO: 307) and Protein Sequence (SEQ ID NO: 308) of Bt1.8 ttt cgt ggc agg aat ccc gca gcc aac gac aaa agg Phe Arg Gly Arg Asn Pro Ala Ala Asn Asp Lys Arg tct gac ctg gcc get ctg agc gtc agg gga gga tgc Ser Asp Leu Ala Ala Leu Ser Val Arg Gly Gly Cys tgt tcc cat cct gcc tgt agc gtg act cat cca gag Cys Ser His Pro Ala Cys Ser Val Thr His Pro Glu ctt tgt ggc tgaagacgct gatgccccag gaccctctga Leu Cys Gly accacgacgt

TABLE 87 DNA Sequence (SEQ ID NO: 309) and Protein Sequence (SEQ ID NO: 310) of Bt1.9 tct gat ggc ggg aat gcc gca gcc aaa gcg tct gac Ser Asp Gly Gly Asn Ala Ala Ala Lys Ala Ser Asp ctg atc gct cag acc atc agg gga gga tgc tgt tcc Leu Ile Ala Gln Thr Ile Arg Gly Gly Cys Cys Ser tat cct gcc tgt agc gtg gaa cat caa gac ctt tgt Tyr Pro Ala Cys Ser Val Glu His Gln Asp Leu Cys gat gga aga cgc tgatgctcca ggaccctctg aaccacgacg Asp Gly Arg Arg t

TABLE 88 DNA Sequence (SEQ ID NO: 311) and Protein Sequence (SEQ ID NO: 312) of Ca1.3 tct tat ggc agg aat gcc gca gcc aaa gcg ttt gaa Ser Tyr Gly Arg Asn Ala Ala Ala Lys Ala Phe Glu gtg agt tgc tgt gtc gtt cgc ccc tgt tgg att cgc Val Ser Cys Cys Val Val Arg Pro Cys Trp Ile Arg tat caa gag gaa tgt ctt gaa gca gat ccc agg acc Tyr Gln Glu Glu Cys Leu Glu Ala Asp Pro Arg Thr ctc tga Leu

TABLE 89 DNA Sequence (SEQ ID NO: 313) and Protein Sequence (SEQ ID NO: 314) of Cal.4 tct gat ggc agg aat gcc gca gcc aac gcc ctt gac Ser Asp Gly Arg Asn Ala Ala Ala Asn Ala Leu Asp ctg atc act ctg atc gcc agg caa aat tgc tgt agc Leu Ile Thr Leu Ile Ala Arg Gln Asn Cys Cys Ser att ccc ggc tgt tgg gag aaa tat gga gac aaa tgt Ile Pro Gly Cys Trp Glu Lys Tyr Gly Asp Lys Cys agt gaa gta cgc tga Ser Glu Val Arg

TABLE 90 DNA Sequence (SEQ ID NO: 315) and Protein Sequence (SEQ ID NO: 316) of C1.2 tct gat ggc agg aat gaa gca gcc aac gac gaa gcg Ser Asp Gly Arg Asn Glu Ala Ala Asn Asp Glu Ala tct gac gtg atc gag ctg gcc ctc aag gga tgc tgt Ser Asp Val Ile Glu Leu Ala Leu Lys Gly Cys Cys tcc aac cct gtc tgt cac ttg gag cat cca aac get Ser Asn Pro Val Cys His Leu Glu His Pro Asn Ala tgt ggt aga aga cgc tgatgctcca ggaccctctg Cys Gly Arg Arg Arg aaccacgacg t

TABLE 91 DNA Sequence (SEQ ID NO: 317) and Protein Sequence (SEQ ID NO: 318) of C1.3 tct gat ggc agg aat gcc gca gcc aac gac aaa gcg Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala tct gac ctg gtc gct ctg gcc gtc agg gga tgc tgt Ser Asp Leu Val Ala Leu Ala Val Arg Gly Cys Cys tcc aac cct atc tgt tac ttt aat aat cca cga att Ser Asn Pro Ile Cys Tyr Phe Asn Asn Pro Arg Ile tgt cgt gga aga cgc tgatgctcca ggaccctctg Cys Arg Gly Arg Arg aaccacgacg t

TABLE 92 DNA Sequence (SEQ ID NO: 319) and Protein Sequence (SEQ ID NO: 320) of Ep1.2 tct cat ggc agg aat gcc gca cgc aaa gcg tct gac Ser His Gly Arg Asn Ala Ala Arg Lys Ala Ser Asp ctg atc gct ctg acc gtc agg gaa tgc tgt tct cag Leu Ile Ala Leu Thr Val Arg Glu Cys Cys Ser Gln cct ccc tgt cgc tgg aaa cat cca gaa ctt tgt agt Pro Pro Cys Arg Trp Lys His Pro Glu Leu Cys Ser tga

TABLE 93 DNA Sequence (SEQ ID NO: 321) and Protein Sequence (SEQ ID NO: 322) of G1.1 tct gat ggc agg aat gac gca gcc aaa gcg ttt gac Ser Asp Gly Arg Asn Asp Ala Ala Lys Ala Phe Asp ctg ata tct tcg acc gtc aag aaa gga tgc tgt tcc Leu Ile Ser Ser Thr Val Lys Lys Gly Cys Cys Ser cat cct gcc tgt gcg ggg aat aat caa cat att tgt His Pro Ala Cys Ala Gly Asn Asn Gln His Ile Cys ggc cga aga cgc tgatgctcca ggaccctctg aaccacgacg Gly Arg Arg Arg t

TABLE 94 DNA Sequence (SEQ ID NO: 323) and Protein Sequence (SEQ ID NO: 324) of G1.3 tct gat ggc agg aat gcc gca gcc aac gac caa gcg Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Gln Ala tct gac ctg atg gct gcg acc gtc agg gga tgc tgt Ser Asp Leu Met Ala Ala Thr Val Arg Gly Cys Cys gcc gtt cct tcc tgt cgc ctc cgt aat cca gac ctt Ala Val Pro Ser Cys Arg Leu Arg Asn Pro Asp Leu tgt ggt gga gga cgc tgatgctcca ggaccctctg Cys Gly Gly Gly Arg aaccacgacg t

TABLE 95 DNA Sequence (SEQ ID NO: 325) and Protein Sequence (SEQ ID NO: 326) of Im1.3 ctt gat gaa agg aat gcc gca gcc gac gac aaa gcg Leu Asp Glu Arg Asn Ala Ala Ala Asp Asp Lys Ala tct gac ctg atc gct caa atc gtc agg aga gga tgc Ser Asp Leu Ile Ala Gln Ile Val Arg Arg Gly Cys tgt tcc cat cct gcc tgt aac gtg aat aat cca cac Cys Ser His Pro Ala Cys Asn Val Asn Asn Pro His att tgt ggt tga Ile Cys Gly

TABLE 96 DNA Sequence (SEQ ID NO: 327) and Protein Sequence (SEQ ID NO: 328) of Lv1.2 tct gat ggc agg aat act gca gcc aaa gtc aaa tat Ser Asp Gly Arg Asn Thr Ala Ala Lys Val Lys Tyr tct aag acg ccg gag gaa tgc tgt ccc aat cct ccc Ser Lys Thr Pro Glu Glu Cys Cys Pro Asn Pro Pro tgt ttc gcg aca aat tcg gat att tgt ggc gga aga Cys Phe Ala Thr Asn Ser Asp Ile Cys Gly Gly Arg cgc tgatgctcca ggaccctctg aaccacgacg t Arg

TABLE 97 DNA Sequence (SEQ ID NO: 329) and Protein Sequence (SEQ ID NO: 330) of Lv1.3 tct aat ggc agg aat gcc gca gcc aaa ttc aaa gcg Ser Asn Gly Arg Asn Ala Ala Ala Lys Phe Lys Ala cct gcc ctg atg aag cgg acc gtc agg gat gct tgc Pro Ala Leu Met Lys Arg Thr Val Arg Asp Ala Cys tgt tca gac cct cgc tgt tcc ggg aaa cat caa gac Cys Ser Asp Pro Arg Cys Ser Gly Lys His Gln Asp ctg tgt ggc tgaagacgct gatgctccag gaccctctga Leu Cys Gly accacgacgt

TABLE 98 DNA Sequence (SEQ ID NO: 331) and Protein Sequence (SEQ ID NO: 332) of Lv1.4 tct aat ggc agg aat gcc gca gcc aaa ttc aaa gcg Ser Asn Gly Arg Asn Ala Ala Ala Lys Phe Lys Ala cct gcc ctg atg gag ctg acc gtc agg gaa gat tgc Pro Ala Leu Met Glu Leu Thr Val Arg Glu Asp Cys tgt tca gac cct cgc tgt tcc gtg gga cat caa gac Cys Ser Asp Pro Arg Cys Ser Val Gly His Gln Asp ctg tgt ggc tgaagacgct gatgctccag gaccctctga Leu Cys Gly Accacgacgt

TABLE 99 DNA Sequence (SEQ ID NO: 333) and Protein Sequence (SEQ ID NO: 334) of Lv1.6 gca ttt gat ggc agg aat gct gca gcc agc gac aaa Ala Phe Asp Gly Arg Asn Ala Ala Ala Ser Asp Lys gcg tcc gag ctg atg gct ctg gcc gtc agg gga tgc  Ala Ser Glu Leu Met Ala Leu Ala Val Arg Gly Cys tgt tcc cat cct gcc tgt gct ggg agt aat gca cat  Cys Ser His Pro Ala Cys Ala Gly Ser Asn Ala His atc tgt ggc aga aga cgc tgatgctcca ggaccctctg Ile Cys Gly Arg Arg Arg aaccacgacg t

TABLE 100 DNA Sequence (SEQ ID NO: 335) and Protein Sequence (SEQ ID NO: 336) of Lv1.7 tct aat ggc agg aat gcc gca gcc aaa ttc aaa gcg Ser Asn Gly Arg Asn Ala Ala Ala Lys Phe Lys Ala cct gcc ctg atg aag ctg acc gtc agg gag gat tgc Pro Ala Leu Met Lys Leu Thr Val Arg Glu Asp Cys tgt tca gac cct cgc tgt tcc gtg gga cat caa gac Cys Ser Asp Pro Arg Cys Ser Val Gly His Gln Asp atg tgt ggc tgaagacgct gatgctccag gaccctctga Met Cys Gly atcacgacgt

TABLE 101 DNA Sequence (SEQ ID NO: 337) and Protein Sequence (SEQ ID NO: 338) of Lv1.8 ttt gaa tgc agg aat gct gca ggc aac gac aaa gcg Phe Glu Cys Arg Asn Ala Ala Gly Asn Asp Lys Ala act gac ctg atg gct ctg act gtc agg gga tgc tgt Thr Asp Leu Met Ala Leu Thr Val Arg Gly Cys Cys tcc cat cct gcc tgt gct ggg aat aat cca cat atc Ser His Pro Ala Cys Ala Gly Asn Asn Pro His Ile tgc ggc tgaagacgct gatgctccag gaccctctga Cys Gly accacgacgt

TABLE 102 DNA Sequence (SEQ ID NO: 339) and Protein Sequence (SEQ ID NO: 340) of Lv1.9 ttt gat ggc agg aac gcc gca gcc aac aac aaa gcg Phe Asp Gly Arg Asn Ala Ala Ala Asn Asn Lys Ala act gat ctg atg gct ctg act gtc aga gga tgc tgt Thr Asp Leu Met Ala Leu Thr Val Arg Gly Cys Cys ggc aat cct tca tgt agc atc cat att cct tac gtt Gly Asn Pro Ser Cys Ser Ile His Ile Pro Tyr Val tgt aat tagagacact gatgctccag gaccctctga Cys Asn accacgacgt

TABLE 103 DNA Sequence (SEQ ID NO: 341) and Protein Sequence (SEQ ID NO: 342) of Lv1.10 tct aat ggc agg aat gcc gca gcc aaa ttc aaa gcg Ser Asn Gly Arg Asn Ala Ala Ala Lys Phe Lys Ala cct gcc ctg atg aag cgg acc gac agc gaa gaa tgc Pro Ala Leu Met Lys Arg Thr Asp Ser Glu Glu Cys tgt tta gac tct cgc tgt gcc ggg caa cat caa gac Cys Leu Asp Ser Arg Cys Ala Gly Gln His Gln Asp ctg tgt ggc gga aga cgc tgatgctcca ggaccctctg Leu Cys Gly Gly Arg Arg aaccacgacg t

TABLE 104 DNA Sequence (SEQ ID NO: 343) and Protein Sequence (SEQ ID NO: 344) of Mr1.3 tct gat ggc agg aat gcc gca gcc aag gac aaa gcg Ser Asp Gly Arg Asn Ala Ala Ala Lys Asp Lys Ala tct gac ctg gtc gct ctg acc gtc aag gga tgc tgt Ser Asp Leu Val Ala Leu Thr Val Lys Gly Cys Cys tct aat cct ccc tgt tac gcg aat aat caa gcc tat Ser Asn Pro Pro Cys Tyr Ala Asn Asn Gln Ala Tyr tgt aat gga aga cgc tga Cys Asn Gly Arg Arg

TABLE 105 DNA Sequence (SEQ ID NO: 345) and Protein Sequence (SEQ ID NO: 346) of Mr1.4 tct gat ggc agg aat gcc gca gcc aag gac aaa gcg Ser Asp Gly Arg Asn Ala Ala Ala Lys Asp Lys Ala tct gac ctg gtc gct ctg acc gtc aag gga tgc tgt Ser Asp Leu Val Ala Leu Thr Val Lys Gly Cys Cys tct cat cct gcc tgt agc gtg aat aat cca gac att Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Ile tgt ggt tga Cys Gly

TABLE 106 DNA Sequence (SEQ ID NO: 347) and Protein Sequence (SEQ ID NO: 348) of Ms1.1 tct gat ggc agg aat gct gca gcc aac aac aaa gtg Ser Asp Gly Arg Asn Ala Ala Ala Asn Asn Lys Val gct ttg acc atg agg gga aaa tgc tgt atc aat gat Ala Leu Thr Met Arg Gly Lys Cys Cys Ile Asn Asp gcg tgt cgc tcg aaa cat cca cag tac tgt tct gga Ala Cys Arg Ser Lys His Pro Gln Tyr Cys Ser Gly aga cgc tgatactcca ggaccctctg aaccacgacg t Arg Arg

TABLE 107 DNA Sequence (SEQ ID NO: 349) and Protein Sequence (SEQ ID NO: 350) of Ms1.6 tct gat ggc agg aat gct gca gcc aac gac aaa gtg Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Val tct gac cag atg gct ctg gtt gtc agg gga tgc tgt Ser Asp Gln Met Ala Leu Val Val Arg Gly Cys Cys tac aat att gcc tgt aga att aat aat cca cgg tac Tyr Asn Ile Ala Cys Arg Ile Asn Asn Pro Arg Tyr tgt cgt gga aaa cgc tgatgttcca ggaccctctg Cys Arg Gly Lys Arg aaccacgacg t

TABLE 108 DNA Sequence (SEQ ID NO: 351) and Protein Sequence (SEQ ID NO: 352) of O1.1 tctgaaggca ggaatgccgc agccaacgac aaagcgtctg acctgatggc t ctg aac gtc agg gga tgc tgt tcc cat              Leu Asn Val Arg Gly Cys Cys Ser His cct gtc tgt cgc ttc aat tat cca aaa tat tgt ggt Pro Val Cys Arg Phe Asn Tyr Pro Lys Tyr Cys Gly gga aga cgc tgatggtcca ggaccctctg aaccacgacg t Gly Arg Arg

TABLE 109 DNA Sequence (SEQ ID NO: 353) and Protein Sequence (SEQ ID NO: 354) of O1.2 tctgatggcg ggaatgccgc agcaaaagcg tttgatctaa tcact ctg gcc ctc agg gat gaa tgc tgt gcc agt cct ccc Leu Ala Leu Arg Asp Glu Cys Cys Ala Ser Pro Pro tgt cgt ttg aat aat cca tac gta tgt cat Cys Arg Leu Asn Asn Pro Tyr Val Cys His tgacgacgct gatgctccag gaccctctga accacgacgt

TABLE 110 DNA Sequence (SEQ ID NO: 355) and Protein Sequence (SEQ ID NO: 356) of O1.4 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ccc act tca gat cgt gca tct gat Thr Val Val Ser Pro Thr Ser Asp Arg Ala Ser Asp agg agg aat gcc gca gcc aaa gcg ttt gac ctg aga Arg Arg Asn Ala Ala Ala Lys Ala Phe Asp Leu Arg tat tcg acc gcc aag aga gga tgc tgt tcc aat cct Tyr Ser Thr Ala Lys Arg Gly Cys Cys Ser Asn Pro gtc tgt tgg cag aat aat gca gaa tac tgt cgt gaa Val Cys Trp Gln Asn Asn Ala Glu Tyr Cys Arg Glu agt ggc taatgctcca ggaccctctg aaccacgacg t Ser Gly

TABLE 111 DNA Sequence (SEQ ID NO: 357) and Protein Sequence (SEQ ID NO: 358) of O1.7 atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr acc gtc gtt tcc ttc act tca gat cgt gca tct gat Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp ggc ggg aat gtc gca gcg tct cac ctg atc get ctg Gly Gly Asn Val Ala Ala Ser His Leu Ile Ala Leu acc atc aag gga tgc tgt tct cac cct ccc tgt gcc Thr Ile Lys Gly Cys Cys Ser His Pro Pro Cys Ala cag aat aat caa gac tat tgt ggt tgacgacgct  Gln Asn Asn Gln Asp Tyr Cys Gly gatgctccag gaccctctga accacgacgt

TABLE 112 DNA Sequence (SEQ ID NO: 359) and Protein Sequence (SEQ ID NO: 360) of O1.8 atg ttc acc gtg ttt ctg ttg gtt gtc tta tca acc Met Phe Thr Val Phe Leu Leu Val Val Leu Ser Thr acc gtc gtt tcc tcc act tca gat cgt gca tct gat Thr Val Val Ser Ser Thr Ser Asp Arg Ala Ser Asp agg agg aat gcc gca gcc aaa gcg tct gac ctg atg Arg Arg Asn Ala Ala Ala Lys Ala Ser Asp Leu Met tat tcg acc gtc aag aaa gga tgt tgt tcc cat cct Tyr Ser Thr Val Lys Lys Gly Cys Cys Ser His Pro gcc tgt tcg ggg aat aat cga gaa tat tgt cgt gaa Ala Cys Ser Gly Asn Asn Arg Glu Tyr Cys Arg Glu agt ggc taatgctcca ggaccctctg aaccacgacg t Ser Gly

TABLE 113 DNA Sequence (SEQ ID NO: 361) and Protein Sequence (SEQ ID NO: 362) of Om1.2 tttgatggca ggaatgcctc agccgacagc aaagtggctg cccggatcgc t cag atc gac agg gat cca tgc tgt tcc              Gln Ile Asp Arg Asp Pro Cys Cys Ser tat cct gac tgt ggc gcg aat cat cca gag att tgt Tyr Pro Asp Cys Gly Ala Asn His Pro Glu Ile Cys ggt gga aaa cgc tgatgctcca ggaccctctg aaccacgacg Gly Gly Lys Arg t

TABLE 114 DNA Sequence (SEQIDNO: 363) and Protein Sequence (SEQ ID NO: 364) of Om1.3 tctcatggca ggaatgccgc acgct ctg acc gtc agg gaa                             Leu Thr Val Arg Glu tgc tgt tct cag cct cct tgt cgc tgg aaa cat cca Cys Cys Ser Gln Pro Pro Cys Arg Trp Lys His Pro gaa ctt tgt agt tgaagacgct gatgctccag gaccctctga Glu Leu Cys Ser accacgacgt

TABLE 115 DNA Sequence (SEQ ID NO: 365) and Protein Sequence (SEQ ID NO: 366) of Om1.4 tttgatggca ggaatgctgc agccagcgac aaagcgtctg agctgatggc t ctg gcc gtc agg gga tgc tgt tcc cat              Leu Ala Val Arg Gly Cys Cys Ser His cct gcc tgt get ggg aat aat cca cat atc tgt ggc Pro Ala Cys Ala Gly Asn Asn Pro His Ile Cys Gly aga aga cgc tgatgctcca ggaccctctg aaccacgacg t Arg Arg Arg

TABLE 116 DNA Sequence (SEQ ID NO: 367) and Protein Sequence (SEQ ID NO: 368) of Om1.5 tctggtgtca ggaaagacgc agcgcctggc ctgatcgct ctg                                            Leu  acc atc aag gga tgc tgt tct gat cct agc tgt aac Thr Ile Lys Gly Cys Cys Ser Asp Pro Ser Cys Asn gtg aat aat cca gac tat tgt ggt tgacgacgct  Val Asn Asn Pro Asp Tyr Cys Gly gatgctccag gaccctctga accacgacgt

TABLE 117 DNA Sequence (SEQ ID NO: 369) and Protein Sequence (SEQ ID NO: 370) of Om1.6 tctaatggca ggaatgccgc agccaaattc aaagcgcctg ccctgatgga g ctg acc gtc agg gaa gaa tgc tgt tcc              Leu Thr Val Arg Glu Glu Cys Cys Ser gac cct cgc tgt tcc gtg gga cat caa gat atg tgt Asp Pro Arg Cys Ser Val Gly His Gln Asp Met Cys  cgg tgaagcacgt gatgctccag gaccctctga accacgacgt Arg

TABLE 118 DNA Sequence (SEQ ID NO: 371) and Protein Sequence (SEQ ID NO: 372) of P1.4 act gat ggc agg aat gct gca gcc ata gcg ctt gac Thr Asp Gly Arg Asn Ala Ala Ala Ile Ala Leu Asp ctg atc gct ccg gcc gtc agg gga gga tgc tgt tcc Leu Ile Ala Pro Ala Val Arg Gly Gly Cys Cys Ser aat cct gcc tgt tta gtg aat cat cta gaa atg tgt Asn Pro Ala Cys Leu Val Asn His Leu Glu Met Cys ggt aaa aga cgc tgatgcccca ggaccctctg aaccacgacg Gly Lys Arg Arg t

TABLE 119 DNA Sequence (SEQ ID NO: 373) and Protein Sequence (SEQ ID NO: 374) of P1.5 tct gat ggc agg gat gcc gca gcc aac gac aaa gcg Ser Asp Gly Arg Asp Ala Ala Ala Asn Asp Lys Ala tct gac ctg atc gct ctg acc gcc agg aga gat cca Ser Asp Leu Ile Ala Leu Thr Ala Arg Arg Asp Pro tgc tgt ttc aat cct gcc tgt aac gtg aat aat cca Cys Cys Phe Asn Pro Ala Cys Asn Val Asn Asn Pro cag att tgt ggt tgaagacgct gatgctccag gaccctctga Gln Ile Cys Gly accacgacgt

TABLE 120 DNA Sequence (SEQ ID NO: 375) and Protein Sequence (SEQ ID NO: 376) of P1.6 tct gat ggc agg gat gct gag aaa aca ggc ttt gac Ser Asp Gly Arg Asp Ala Glu Lys Thr Gly Phe Asp acg acc att gtg ccg gaa gac tgc tgt tcg gat cct Thr Thr Ile Val Pro Glu Asp Cys Cys Ser Asp Pro tcc tgt tgg agg ctg cat agt tta get tgt act gga Ser Cys Trp Arg Leu His Ser Leu Ala Cys Thr Gly att gta aac cgc tgatgctcca ggaccctctg aaccacgacg Ile Val Asn Arg t

TABLE 121 DNA Sequence (SEQ ID NO: 377) and Protein Sequence (SEQ ID NO: 378) of P1.8 act gat ggc agg agt gct gca gcc ata gcg ttt gcc Thr Asp Gly Arg Ser Ala Ala Ala Ile Ala Phe Ala ctg atc gct ccg acc gtc tgc tgt act aat cct gcc Leu Ile Ala Pro Thr Val Cys Cys Thr Asn Pro Ala tgt ctc gtg aat aat ata cgc ttt tgt ggt gga aga Cys Leu Val Asn Asn Ile Arg Phe Cys Gly Gly Arg cgc tgatgcccca ggaccctctg aaccacgacg t Arg

TABLE 122 DNA Sequence (SEQ ID NO: 379) and Protein Sequence (SEQ ID NO: 380) of Rg1.1 tct gat gga aga aat gcc gca agc gac gcc aaa gcg Ser Asp Gly Arg Asn Ala Ala Ser Asp Ala Lys Ala ttt ccc cgg atc get cca atc gtc agg gac gaa tgc Phe Pro Arg Ile Ala Pro Ile Val Arg Asp Glu Cys tgt agc gat cct agg tgt cac ggg aat aat cgg gac Cys Ser Asp Pro Arg Cys His Gly Asn Asn Arg Asp cac tgt gct tgaagacgct gctgctccag gaccctctga His Cys Ala accacgacgt

TABLE 123 DNA Sequence (SEQ ID NO: 381) and Protein Sequence (SEQ ID NO: 382) of Rg1.3 tct gat ggc agg aat acc gcg gcc gac gaa aaa gcg Ser Asp Gly Arg Asn Thr Ala Ala Asp Glu Lys Ala tcc gac ctg atc tct caa act gtc aag aga gat tgc Ser Asp Leu Ile Ser Gln Thr Val Lys Arg Asp Cys tgt tcc cat cct ctc tgt aga tta ttt gtt cca gga Cys Ser His Pro Leu Cys Arg Leu Phe Val Pro Gly ctt tgt att tgaagacgctgctgctccag gaccctctga Leu Cys Ile accacgact

TABLE 124 DNA Sequence (SEQ ID NO: 383) and Protein Sequence (SEQ ID NO: 384) of Rg1.4 tct gat ggc agg aat gcc gca gcc gac aac aaa gcg tct gac cta atc Ser Asp Gly Arg Asn Ala Ala Ala Asp Asn Lys Ala Ser Asp Leu Ile get caa atc gtc agg aga gga tgc tgt tcc cat cct gtc tgt aaa gtg Ala Gln Ile Val Arg Arg Gly Cys Cys Ser His Pro Val Cys Lys Val agg tat cca gac ctg tgt cgt tgaagacgct gctgctccag gaccctctga Arg Tyr Pro Asp Leu Cys Arg accacgacgt

TABLE 125 DNA Sequence (SEQ ID NO: 385) and Protein Sequence (SEQ ID NO: 386) of Rg1.5 tct gat ggc agg aat gcc gca gcc gac aac aga gcg tct gac cta atc Ser Asp Gly Arg Asn Ala Ala Ala Asp Asn Arg Ala Ser Asp Leu Ile gct caa atc gtc agg aga gga tgc tgt tcc cat cct gcc tgt aat gtg Ala Gln Ile Val Arg Arg Gly Cys Cys Ser His Pro Ala Cys Asn Val aat aat cca cac att tgt ggt tgaagacgct gctgctccag gaccctctga Asn Asn Pro His Ile Cys Gly accacgacgt

TABLE 126 DNA Sequence (SEQ ID NO: 387) and Protein Sequence (SEQ ID NO: 388) of Rg1.8 tct gat ggc agg aat gcc gca gcc gac aac aaa ccg tct gac cta atc Ser Asp Gly Arg Asn Ala Ala Ala Asp Asn Lys Pro Ser Asp Leu Ile gct caa atc gtc agg aga gga tgc tgt tcg cat cct gtc tgt aaa gtg Ala Gln Ile Val Arg Arg Gly Cys Cys Ser His Pro Val Cys Lys Val agg tat tca gac atg tgt ggt tgaagacgct gctgctccag gaccctctga Arg Tyr Ser Asp Met Cys Gly accacgacgt

TABLE 127 DNA Sequence (SEQ ID NO: 389) and Protein Sequence (SEQ ID NO: 390) of Sm1.4 tct gat ggc agg aat gca gag cga cga caa agc gtc tgt cct ggt cgc Ser Asp Gly Arg Asn Ala Glu Arg Arg Gln Ser Val Cys Pro Gly Arg tct ggc ccc agg gga gga tgt tgt tcc cac cct gcc tgt aag gtg cat Ser Gly Pro Arg Gly Gly Cys Cys Ser His Pro Ala Cys Lys Val His ttt cca cac agt tgt ggt tgacgacgct gatgctccag gaccctctga Phe Pro His Ser Cys Gly accacgacgt

TABLE 128 DNA Sequence (SEQ ID NO: 391) and Protein Sequence (SEQ ID NO: 392) of Sm1.5 tct gat ggc agg aat gcc gca gcc agc gac aga gcg tct gac gcg gcc Ser Asp Gly Arg Asn Ala Ala Ala Ser Asp Arg Ala Ser Asp Ala Ala cac cag gta tgc tgt tcc aac cct gtc tgt cac gtg gat cat cca gaa His Gln Val Cys Cys Ser Asn Pro Val Cys His Val Asp His Pro Glu ctt tgt cgt aga aga cgc tgatgctcca ggaccctctg aaccacgacg t Leu Cys Arg Arg Arg Arg

TABLE 129 DNA Sequence (SEQ ID NO: 393) and Protein Sequence (SEQ ID NO: 394) of S1.5 tct gat ggc agg aat gcc gcg gcc aac gac aaa gcg tct gac ctg gtc Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala Ser Asp Leu Val gct ccg gcc atc agg gga tgc tgt tcc cac cct gtc tgt aac ttg agt Ala Pro Ala Ile Arg Gly Cys Cys Ser His Pro Val Cys Asn Leu Ser aat cca caa att tgt cgt gga aga cgc tgatgctcca ggaccctctg Asn Pro Gln Ile Cys Arg Gly Arg Arg aaccacgacg t

TABLE 130 DNA Sequence (SEQ ID NO: 395) and Protein Sequence (SEQ ID NO: 396) of Tx1.5 ttt cat ggc agg aat gcc gca gcc aaa gcg tct ggc ctg gtc ggt ctg Phe His Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu Val Gly Leu acc gac aag agg caa gaa tgc tgt tct cat cct gcc tgt aac gta gat Thr Asp Lys Arg Gln Glu Cys Cys Ser His Pro Ala Cys Asn Val Asp cat cca gaa att tgt cgt tga His Pro Glu Ile Cys Arg

TABLE 131 DNA Sequence (SEQ ID NO: 397) and Protein Sequence (SEQ ID NO: 398) of T1.1 act gat ggc agg agt gct gca gcc ata gcg ttt gcc ctg atc gct ccg Thr Asp Gly Arg Ser Ala Ala Ala Ile Ala Phe Ala Leu Ile Ala Pro acc gtc tgg gaa gga tgc tgt tct aat cct gcc tgt ctc gtg aat cat Thr Val Trp Glu Gly Cys Cys Ser Asn Pro Ala Cys Leu Val Asn His ata cgc ttt tgt ggt gga aga cgc tgatgcccca ggaccctctg aaccacgacg Ile Arg Phe Cys Gly Gly Arg Arg t

TABLE 132 DNA Sequence (SEQ ID NO: 399) and Protein Sequence (SEQ ID NO: 400) of Vr1.3 tct aat ggc atg aat gcc gca gcc atc agg aaa gcg tct gcc ctg gtg Ser Asn Gly Met Asn Ala Ala Ala Ile Arg Lys Ala Ser Ala Leu Val gct cag atc gcc cat cga gac tgc tgt gac gat cct gcc tgc acc gtg Ala Gln Ile Ala His Arg Asp Cys Cys Asp Asp Pro Ala Cys Thr Val aat aat cca ggc ctt tgc act tgaagatgct gctgccccag gaccctctga Asn Asn Pro Gly Leu Cys Thr accacgacgt

TABLE 133 DNA Sequence (SEQ ID NO: 401) and Protein Sequence (SEQ ID NO: 402) of G1.2 tct gat ggc ggg aat gcc gca gca aaa gag tct gac gtg atc gct ctg Ser Asp Gly Gly Asn Ala Ala Ala Lys Glu Ser Asp Val Ile Ala Leu acc gtc tgg aaa tgc tgt acc att cct tcc tgt tat gag aaa aaa aaa Thr Val Trp Lys Cys Cys Thr Ile Pro Ser Cys Tyr Glu Lys Lys Lys att aaa gca tgt gtc ttt tgacgacgct gatgctccag gaccctctga Ile Lys Ala Cys Val Phe accacgacgt

TABLE 134 DNA Sequence (SEQ ID NO: 403) and Protein Sequence (SEQ ID NO: 404) of Rg1.12 tct gat ggc gca gtc gac gac aaa gcg ttg gat cga atc gct gaa atc Ser Asp Gly Ala Val Asp Asp Lys Ala Leu Asp Arg Ile Ala Glu Ile gtc agg aga gga tgc tgt ggc aat cct gcc tgt agc ggc tcc tcg aaa Val Arg Arg Gly Cys Cys Gly Asn Pro Ala Cys Ser Gly Ser Ser Lys gat gca ccc tct tgt ggt tgaagacgct gctgctccag gaccctctga Asp Ala Pro Ser Cys Gly accacgacgt

It will be appreciated that the methods and compositions of the instant invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent to the artisan that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.

BIBLIOGRAPHY

-   Barnay, G. et al. (2000). J. Med. Chem. -   Bitan, G. et al. (1997). J. Peptide Res. 49:421-426. -   Blount, K. et al. (1992). Toxicon 30:835-842. -   Bodansky et al. (1966). Chem. Ind. 38:1597-98. -   Cartier, G. E. et al. (1996). J. Biol. Chem. 271:7522-7528. -   Cruz, L. J. at al. (1976). Verliger 18:302-308. -   Cruz, L. J. et al. (1987). J. Biol. Chem. 260:9280-9288. -   Fainzilber, M. et al. (1994). Biochemistry 33:9523-9529. -   Gray, W. R. et al. (1981). J. Biol. Chem. 256:4734-4740. -   Haack, J. A. et al. (1990). J. Biol. Chem. 265:6025-6029. -   Horiki, K. et al. (1978). Chemistry Letters 165-68. -   Hubry, V. et al. (1994). Reactive Polymers 22:231-241. -   Jacobsen, R. et al. (1997). J. Biol. Chem. 272:22531-22537. -   Johnson, D. S. et al. (1995). Mol. Pharmacol. 48:194-199. -   Kapoor (1970). J. Pharm. Sci. 59:1-27. -   Kornreich, W. D. et al. (1986). U.S. Pat. No. 4,569,967. -   Luo, S. et al. (1998). J. Neurosci. 18:8571-8679. -   Marshall, I. G. and Harvey, A. L. (1990). Toxicon 28:231-234. -   Martinez, J. S. et al. (1995). Biochem. 34:14519-14526. -   McIntosh, J. M. et al. (1982). Arch. Biochem. Biophys. 218:329-334. -   Mena, E. E. et al. (1990). Neurosci. Lett. 118:241-244. -   Methoden der Organischen Chemie (Houben-Weyl): Synthese von     Peptiden, E. Wunsch (Ed.), Georg Thieme Verlag, Stuttgart, Ger.     (1974). -   Myers, R. A. et al. (1991). Biochemistry 30:9370-9377. -   Nishiuchi, Y. et al. (1993). Int. J. Pept. Protein Res. 42:533-538. -   Nowak, L. et al. (1984). Nature 307:462-465. -   Olivera, B. M. et al. (1984). U.S. Pat. No. 4,447,356. -   Olivera, B. M. et al. (1985). Science 230:1338-1343. -   Olivera, B. M. et al. (1996). U.S. Pat. No. 5,514,774. -   Rivier, J. R. et al. (1978). Biopolymers 17:1927-38. -   Rivier, J. R. et al. (1987). Biochem. 26:8508-8512. -   Sambrook, J. et al. (1989). Molecular Cloning: A Laboratory Manual,     2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. -   Schroder & Lubke (1965). The Peptides 1:72-75, Academic Press, NY. -   Shon, K.-J. et al. (1994). Biochemistry 33:11420-11425. -   Stewart and Young, Solid-Phase Peptide Synthesis, Freeman & Co., San     Francisco, Calif. (1969). -   Vale et al. (1978). U.S. Pat. No. 4,105,603. -   Van de Steen, P. et al. (1998). Critical Rev. in Biochem. and Mol.     Biol. 33:151-208. -   Zafaralla, G. C. et al. (1988). Biochemistry 27:7102-7105. -   Zhou L. M., et al. (1996). J. Neurochem. 66:620-628. -   U.S. Pat. No. 3,972,859. -   U.S. Pat. No. 3,842,067. -   U.S. Pat. No. 3,862,925. -   U.S. Pat. No. 5,550,050. -   PCT Published Application WO 92/19195. -   PCT Published Application WO 94/25503. -   PCT Published Application WO 95/01203. -   PCT Published Application WO 95/05452. -   PCT Published Application WO 96/02286. -   PCT Published Application WO 96/02646. -   PCT Published Application WO 96/11698. -   PCT Published Application WO 96/40871. -   PCT Published Application WO 96/40959. -   PCT Published Application WO 97/12635. 

1. An isolated pure α-conotoxin peptide comprising the amino acid sequence of: Gly-Cys-Cys-Ser-His-Xaa₅-Ala-Cys-Ser-Val-Asn-His-Xaa₅-Xaa₁-Leu-Cys (SEQ ID NO:34); wherein Xaa₁ is Glu or γ-carboxy-Glu (Gla) and Xaa₅ is Pro or hydroxy-Pro; wherein the C-terminus contains a hydroxyl group or an amide group; wherein the His residue may be substituted with a halo-His residue; and wherein the Cys residues may be in the D or L configuration or substituted with homocysteine in the D or L configuration.
 2. The isolated α-conotoxin peptide of claim 1, wherein Xaa₁ is Glu.
 3. The isolated α-conotoxin peptide of claim 1, wherein Xaa₅ is Pro.
 4. The isolated α-conotoxin peptide of claim 1, wherein Xaa₁ is Glu and Xaa₅ is Pro.
 5. The isolated α-conotoxin peptide of claim 1, wherein the halo-His is iodo-His.
 6. The substantially pure α-conotoxin peptide of claim 1, which is modified to contain an O-glycan, an S-glycan or an N-glycan.
 7. An isolated pure α-conotoxin peptide precursor comprising the amino acid sequence of SEQ ID NO:111. 